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ABSTRACT 
INTRODUCTION: Stone incidence in South African blacks is extremely rare. The 
hypothesis to be tested is whether this apparent immunity can be attributed to the presence 
of more potent inhibitors of calcium oxalate (CaOx) crystallisation in urine from blacks 
compared to those occurring in the urine of white subjects. Urinary proteins have been 
shown to be inhibitors. This study investigated the crystallisation inhibitory properties of 
albumin isolated from the urine of healthy black (BA) and healthy white (W A) South 
Africans as well as those of human serum albumin (HSA). Albumin was selected because 
previous studies on other population groups had revealed that the protein inhibits CaOx 
aggregation. This observation is significant because crystal aggregation is considered to be 
more important for stone formation than crystal nucleation or growth. METHODS: 
Albumin was isolated from the urine of healthy black and healthy white subjects by 
immunoaffinity chromatography. Commercial HSA was obtained from Sigma. The purity 
of each protein was checked using sodium dodecyl sulphate polyacrylamide Gel 
Electrophoresis (SDS-PAGE) and Western blotting. Crystallisation experiments were 
performed in ultrafiltered urine from the two race groups. These experiments included 
determination of CaOx metastable limit, measuring the kinetics of particle formation in 
supersaturated ultrafiltered urine, Coulter Counter measurements of particle volume-size 
distributions and crystal deposition kinetics using labelled [14C]-oxalate. X-ray diffraction 
analysis was used to confirm the purity of calcium oxalate monohydrate (COM) crystals 
prepared in vitro and to confirm the composition of calcium oxalate crystals induced in 
urine samples as part of the protocol to isolate albumin. Aggregation inhibition of COM 
crystal slurries by BA, W A and HSA was studied in vitro using zeta potentials and 
sedimentation rates. RESUL TS: The concentration on urinary albumin was determined 
to be 0.802 mgll in blacks and 0.743 mgll in whites. The metastable limit of ultrafiltered 
urine from blacks (BUF) and whites (WUF) was 0.100 mol/dm3 and 0.045 mol/dm3 
respectively. Data acquired by spectrophotometry, Coulter Counter and [14C]-oxalate 
deposition were considered in concert and demonstrated that albumin from both race 
groups inhibits the crystallisation of CaOx. The data also suggested the occurrence of 
independent protein co-precipitation i.e. adsorption of the protein directly onto CaOx 
crystal surfaces. X-ray diffraction data demonstrated that urine from blacks and whites 
contained calcium oxalate dihydrate (COD) crystals and a mixture of COM and COD 
respectively. Zeta potential measurements and sedimentation rates were used to 
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investigate the effect of albumin on calcium oxalate monohydrate (COM) crystal 
aggregation. The zeta potential of COM crystal slurries increased in the presence of all 
three proteins. Values followed the trend BA (-19.3 mY), WA (-16.9 mY), HSA (-14.2 
mY) and COM control crystals (-13.0 mY). The percentage inhibition of aggregation by 
HSA and W A, as determined from sedimentation experiments, was not significantly 
different, (3l.3 % versus 35.1 % respectively) while inhibition of COM crystal aggregation 
by BA was significantly higher at 50 %. CONCLUSION: The results have shown that 
BUF can tolerate higher levels of supersaturation without the formation of CaOx crystals, 
compared to WUF. Results obtained by spectrophotometry, Coulter Counter and C4C]-
oxalate deposition demonstrated that albumin, regardless of its source, inhibits the rate of 
formation of CaOx and that BA is more efficacious in this regard. It is suggested that the 
formation of COD over COM in the urine of healthy black subjects would be 
advantageous. Measurements of zeta potentials and sedimentation rates confirmed that 
albumin, irrespective of its origin, is an inhibitor of COM crystal aggregation and that BA 
is superior to W A and HSA in this regard. It was concluded that albumin may playa 
contributory role to the overall immunity of the black population group in South Africa to 
urolithiasis. 
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CHAPTER 1: INTRODUCTION 
1.1 Kidney Stone Disease 
The human body is a network of sophisticated systems working harmoniously together to 
sustain life. We are often oblivious to how well-coordinated these systems are until 
something goes wrong. Many of the chemical processes in the body release toxins into the 
bloodstream. If allowed to remain, these can lead to serious complications, even death. 
They have to be continuously filtered and removed. This filtering is one of the principal 
functions of the kidneys. The nephron is the basic filtration unit. There are over a million 
nephrons in each kidney (Davidson, 1981). 
Briefly, as blood is forced through the glomerulus, water, waste products, salts and other 
molecules are filtered into Bowman's capsule. The resulting glomerular filtrate now flows 
down in the proximal convoluted tubules, where re-absorption of water, glucose, other 
nutrients, sodium and other ions occurs. Re-absorption continues in the loop of Henle, 
distal convoluted tubules and collecting tubules. As the fluid moves through the distal and 
collecting ducts, cells in the tubule wall release additional secretions into it including 
ammonia, potassium, hydrogen ions, urea, uric acid and excess water (Davidson, 1981). 
The final product is urine. 
It is in this biochemical milieu that renal calculi develop. Urinary stones are polycrystalline 
masses found anywhere along the urinary tract - kidneys, ureters, bladder and urethra as 
illustrated in Fig 1 (Gill et aI., 1974; Hess et aI., 1996). The term nephrolithiasis is used to 
refer to the whole clinical picture due to the formation and passage in the urinary tract of 
these calculi or stones (Ramello et aI., 2000). 
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Fig 1: Urinary stones form anywhere along the urinary tract taken from www.transweb.org 
The different types of kidney stones are composed of calcium oxalate, calcium phosphate, 
uric acid, cystine or magnesium ammonium phosphate (Coe et aI., 1980). Calcium oxalate 
is the major constituent of over 80 % of urinary calculi, and whewellite (calcium oxalate 
monohydrate) forms the central core (probably the nidus) in 70 % of upper urinary tract 
calculi (Elliot, 1973; Gill et aI., 1974). Some authors (Grases et aI., 1988) argue that a 
closer examination of such a nidus will reveal calcium phosphate at the center. 
Crystallisation of calcium oxalate and calcium phosphate from urine, therefore, would 
seem to be obligatory for stone disease. An essential condition for a crystal to grow from a 
solution is supersaturation (Hess et aI., 1996; Kavanagh, 2000). 
There are six accepted factors that have been shown to increase the risk of calcium stones. 
These risk factors are considered to affect the degree of saturation of urine with calcium 
oxalate and calcium phosphate. They are, a low urine volume; increases in the excretion of 
calcium, oxalate and uric acid; decreases in the excretion of the glycosaminoglycan (GAG) 
inhibitors of crystallisation and fluctuations in pH (Robertson et aI., 1981). There is debate 
about whether it is the increase or decrease in pH that increases the risk of stone formation. 
In the model of calcium stone formation, illustrated in Fig 2, the authors proposed that an 
increase in pH favours stone formation because solubility of CaOx decreases with 
increasing pH (Robertson et aI., 1981; Robertson et aI., 1983). However, subsequent 
studies have demonstrated that the inhibition of calcium oxalate crystal growth in urine 
from stone-formers increased with increasing pH, implying that consumption of foods or 
beverages that decrease pH would represent an increased risk of stone formation (Tiselius, 
1981; Hess et aI., 1999; Rodgers, 1999). At a higher pH, more phosphate and citrate ions 
2 
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become dissociated; this augments the complexation of calcium thereby lowering the 
urinary saturation of stone forming salts (Pak, 1994). 
The risk factor model for calcium oxalate stone formation proposed by Robertson and 
colleagues (1981), shows how epidemiological factors can increase or decrease the effect 
of the above mentioned risk factors (Fig 2). These risk factors in turn affect urinary 
supersaturation with respect to calcium oxalate (CaOx) or calcium phosphate (CaP). If the 
overall effect is an increase in supersaturation and a decrease in the activity of urinary 
inhibitors, then the result will be rapid crystal formation and growth which will lead to 
stone fornlation (Robertson et al., 1981). 
Pre-urinary 
Risk Factors 
Sex 
Age 
Occupation 
Social Class 
Climate 
Diet & Fluid Intake 
Metabolic 
Genetic 
Urinary 
Risk Factors 
Chemical 
Risk Factors 
upersaturation 
(CaOx & CaP) 
Inhibitory 
activity 
Fig 2: Model (jf calcium stoneformation (Robertson et aI., 1981) 
1.2 Epidemiology of Nephrolithiasis 
Kidney stones are one of the most ancient afflictions of mankind. Ancient Babylonians 
and Egyptians were familiar with stones of the urinary tract. Bladder stones have been 
discovered in Egyptian mummies (Coe et al., 1980). Today, the varied manifestations of 
nephrolithiasis provide an interesting epidemiological study from the standpoints of 
geography, diet, drinking water, profession, age, race and sex. 
3 
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1.2.1 GeograpllY and Climate 
Research into the geographical pathology of stone disease shows that its prevalence is very 
far from constant (al-Hadramy, 1997; Ramello et aI., 2000; Robertson, 2003). The risk of 
developing nephrolithiasis in normal adults is 1-5 % in Asia, 5-9 % in Europe and in North 
America it is 12 % in Canada and 13 % in USA (Ramello et aI., 2000). Saudi Arabia 
reportedly has the highest risk at 20.1 % (Robertson et aI., 1994). In tropical countries 
where individuals consume large quantities of local leaves and vegetables which are high 
in oxalate, the concentration of urinary oxalate is high and, as a result, the ammonium acid 
urate stones which are commonly formed, contain calcium oxalate as well (Robertson, 
2003). Stone composition and location within the urinary tract (bladder or kidney) can 
differ in different countries and even in the same geographical region, clinical and 
metabolic patterns of stone disease can change over time. The following examples, 
extracted from the review by Ramello et aI. (2000) illustrate this point. In India, between 
1965 and 1985 the incidence of bladder stones dropped from 30 % to 5 %. At the same 
time, the prevalence of calcium oxalate (CaOx) stones rose from 26 % to 82 %, and that of 
struvite stones (magnesium ammonium phosphate) diminished from 20 % to 5 %. In 
Japan, bladder stones decreased from 50 % to 5 % between 1950 and 1985. In Portugal, 
over a twenty-year period, the frequency of calcium stones rose from 64 % to 82 %, 
struvite stones decreased from 14 % to 3 % and uric acid stones from 19 % to 12 % 
(Ramello et aI., 2000). 
A study in Perth, Western Australia (Bateson, 1973) was carried out to compare the 
frequency of renal calculi during the hot summer months to its incidence rate during the 
cold and wet winter. Results showed that the prevalence in summer (46 %) was nearly 
double that in winter (25 %). This variation was attributed to excessive water loss by 
perspiration which leads to dehydration in summer. If coupled with inadequate fluid 
intake, an increase in urine super-saturation due to low urine output increases the risk of 
crystalluria and kidney stone formation. People who live in hot climates are therefore 
encouraged to monitor their fluid intake, particularly if they are inclined to form kidney 
stones (Bateson, 1973). 
In a similar study in Leeds (Hallson and Rose, 1977), seasonal crystal incidence was 
compared with seasonal changes in urinary composition. Crystalluria was taken as an 
4 
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indicator of urine super-saturation with the material from which the crystals were 
composed. Individual urine samples from normal subjects and stone-formers with 
idiopathic hypercalciuria were examined for crystals both qualitatively and quantitatively 
at 37°C. The group as a whole showed a rise in incidence of urinary crystals in the 
summer months. This rise was seen most clearly in overnight urines, collected on rising in 
the morning, and the patients appeared to be at a risk overnight during the summer. The 
rise in crystal incidence during the summer was associated with increased creatinine 
concentrations in the same urine samples and with increased oxalate concentration in 24-
hour urine collections (HaUson and Rose, 1977). 
1.2.2 Diet 
During the past 25 years, several important studies have addressed the role of diet in 
calcium oxalate nephrolithiasis (Vahlensieck, 1986; Kok et aL, 1990; Trinchieri et aL, 
1991; Hesse et aL, 1993; Hess et aL, 1994; Goldfarb, 1994; Parivar et aL, 1996; Curhan, 
1999; Massey et aL, 2001; Nguyen et aL, 2001; Rodgers et aL, 2002; Borghi et aL, 2002). 
An important dietary factor which is linked consistently at all demographic levels with 
expenditure on food and the occurrence of stones is the intake of animal protein. 
The effect of modulating dietary factors on actual urinary supersaturations has been studied 
in healthy volunteers (Hesse et aL, 1993). While leaving the ingested amounts of calcium, 
oxalate, and fibre unchanged, a reduction in daily intakes of protein (from 85 to 65 g) and 
purines (from 509 to 219 mg) lowered relative supersaturations of both calcium oxalate 
and uric acid by 58 % and 85 % respectively (Hesse et a1., 1993). A recent study by Hess 
et a1. (1999) went a step further by assessing the direct impact of dietary advice, which 
primarily consisted of increased fluid intake as well as a reduction in meat protein and salt 
consumption, on actual urinary composition and supersaturation in male patients with 
idiopathic calcium urolithiasis (lCSFs). The authors reported that dietary advice which 
solely focused on individual abnormalities of either urine volume or urea excretion rate (as 
a marker for meat protein intake) lowers urinary supersaturations by only 19 % in ICSFs. 
However, in ICSFs in whom dietary advice was able to jointly stimulate increases in urine 
volume and reductions in meat protein intake, the relative supersaturation of calcium 
oxalate (RScaox) and uric acid (RSuA) decreased (Hess et aL, 1999). Thus, consumption of 
animal protein may distinguish renal stone formers from healthy individuals (Robertson et 
5 
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al., 1981; Kok et aI., 1990; Trinchieri et aI., 1991; Giannini et aI., 1999; Massey et aI., 
2001 and Nguyen et aI., 2001). 
Biochemically, a diet high in animal protein increases the urinary excretion of calcium, 
oxalate and uric acid as well as lowers citrate excretion, all of which are well known risk 
factors for idiopathic calcium nephrolithiasis (Hess et aI., 1999). It has been reported that 
in vegetarians, who have a high intake of vegetable protein, compared with animal protein, 
there is a low incidence of upper urinary tract stones. The reason for this is that a diet low 
in animal protein reduces the urinary excretion of calcium, oxalate and uric acid, 3 of the 6 
main urinary risk factors, so that the overall probability of stone formation is very low 
(Robertson et aI., 1979; Vahlensieck, 1986). 
More recently, Massey et aI. (2001) studied the effect of substituting equal amounts of 
dietary protein (beef) for plant protein (legumes, seeds, nuts and grains) on urinary 
components associated with calcium oxalate precipitability risk. The findings of these 
authors is in agreement with previous studies and showed that a balanced diet containing 
moderate amounts of either beef or plant protein coupled with adequate fluid intake is 
effective in reducing the risk of calcium oxalate stone formation (Vahlensieck, 1986; 
Hesse et aI., 1993; Goldfarb, 1994; Parivar et aI., 1996; Giannini et aI., 1999; Massey et aI., 
2001). Therefore, while the risk of stone formation in vegetarians is low, non-vegetarians 
are afforded protection from stone disease by balancing the amount of ingested animal and 
plant protein and increasing their fluid intake. 
Another important dietary factor which has received a huge amount of attention is that of 
calcium ingestion. Oral calcium restriction was traditionally recommended for the 
prevention of calcium nephrolithiasis (Bleich et aI., 1979; Robertson, 1987). However, 
several recent studies have revealed that the restriction of dietary calcium in renal stone 
formers is not warranted (Curhan et aI., 1993; Massey et aI., 1993; Messa et aI., 1997; 
Curhan et aI., 1997; Heller et aI., 1999). Rather, normal dietary calcium intake, along with 
reduced salt and protein, is now advised (Martini et al., 2000; Massey et aI., 200]; Hall, 
2002). There is also evidence that the restriction of dietary calcium leads to an enhanced 
absorption and excretion of oxalate, while an increase in calcium intake results in 
decreased gastrointestinal absorption of dietary oxalate and lower urinary oxalate 
concentrations (Curhan et aI., 1993; Curhan et aI., 1997). 
6 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Dietary oxalate restriction has been found to be beneficial in preventing recurrence of 
calcium oxalate urolithiasis (Pak et aI., 1984; Massey, 2003). Foods that are very high in 
oxalate include spinach, rhubarb, and beets and should be avoided by stone forming 
patients, as they elevate urinary oxalate excretion. Calcium oxalate stone-formers should 
also avoid consumption of large quantities of foods containing higher amounts of oxalate 
such as concentrated wheat bran, chocolate, nuts and berries (Smith, 1991; Massey et aI., 
1993; Massey et al., 1998). de 0 G Mendocana et al. (2003) investigated the effect of an 
oxalate load on urinary oxalate excretion in calcium stone-forming patients. The authors 
reported that a 2-fold increase in oxalate intake produced a significant 20% increase in 
oxaluria, confirming previous observations that hyperoxaluric patients will benefit from 
reduction of dietary oxalate (Tiselius, 1980; Brinkley et aI., 1981; Finch et aI., 1981; 
Larsson et al., 1987). 
1.2.3 High Fluid Intake 
An increase in fluid intake is routinely recommended for patients who have had kidney 
stones to decrease the likelihood of recurrence (Shuster et al., 1982; Vahlensieck, 1986; 
Ackermann et aI., 1988; Weiss et aI., 1992; Coe et al., 1992; Wabner et al., 1993; Curhan 
et al., 1996; Seltzer et aI., 1996; Rodgers, 1997; Curhan et al., 1998; Massey et aI., 1998; 
Rodgers, 1999; Hirvonen et aI., 1999; Goldfarb et aI., 2000; Honow R et al., 2000; Knight 
et aI., 2003). 
Theoretically, a high fluid intake may inhibit stone formation, since it would dilute urine, 
lower urinary concentration of stone-forming constituents, and reduce urinary saturation of 
stone salts. However, it was thought that this strategy would also dilute urinary 
concentration of inhibitors, which normally retard crystallisation of stone salts. It was thus 
feared that the decline in inhibition might negate the beneficial effect of reduced saturation. 
These circumstances led Pak et al. (1980) to examine in detail the effect of urinary dilution 
on the crystallisation of calcium salts. 
Urinary dilution was achieved in vitro (1 to 2 lid) by addition of water to urine from six 
patients with renal stones and two normal subjects, and in vivo (1.023 to 2.383 lid) by an 
increased ingestion of distilled water in four patients with nephrolithiasis and three normal 
7 
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subjects. Both forms of urinary dilution significantly reduced the state of supersaturation 
of calcium oxalate and calcium phosphate. In addition, the metastable limit of calcium 
oxalate significantly increased. The limit of metastability is defined as the minimum 
anl0unt of oxalate necessary to induce nucleation (Ryall et aL, 1985). Thus, urinary 
dilution was found to reduce the tendency for the crystallisation of calcium salts in urine 
by lowering the level of supersaturation and by increasing the minimum supersaturation 
needed to elicit spontaneous nucleation of calcium oxalate (Pak et al., 1980). 
That an increase in fluid intake can reduce the risk for kidney stones has been confirmed 
by recent studies (Curhan et aL, 1998; Borghi et al., 1999). It is recommended that to 
avoid recurrence, stone-formers drink a sufficient amount of fluid to attain urine output of 
21 per day. Increasing fluid intake has been found to prevent recurrence in 60 % of patients 
with idiopathic calcium urolithiasis (Hosking et al., 1983). 
The choice of beverage has also been found to be meaningful since fluid composition 
directly influences urine composition and crystal formation (Hesse et aL, 1993). Although 
water is most commonly imbibed, recent studies have shown that mineral water containing 
calcium and magnesium has therapeutic and prophylactic value in calcium oxalate 
nephrolithiasis (Ackermann et aL, 1988; Rodgers 1997). Epidemiological studies by 
Curhan et aL (1998) suggested that grapefruit juice increased the risk of stone formation. 
However, recent studies have not confirmed this to be so (Goldfarb et aL, 2000; Honow et 
aL, 2000). Similar conflicting studies have been found for alcohol (Vahlensieck, 1986; 
Hirvonen et al., 1999; Knight et aL, 2003). Fluids that have been found to alter risk factors 
favourably include milk (Coe et aL 1992), orange juice (Coe et aL 1992; Wabner et al., 
1993), apple juice (Vahlensieck, 1986; Curhan et aL, 1996; Massey et aL, 1998), cranberry 
juice (McHarg et aL, 2003), herbal teas (Vahlensieck, 1986; Hesse et al., 1993), and 
lemonade (Seltzer et aL, 1996). Fluids that should be avoided by stone formers include 
coffee, tea and carbonated cola drinks (Vahlensieck, 1986; Weiss et aL, 1992; Rodgers, 
1999). 
1.2.4 Profession and Stress Levels 
Occupational conditions have been found to affect susceptibility to stone disease. 
Urolithiasis occurs more frequently in pilots than in the ground-service, probably due to 
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the sedentary nature of their work (Garilevich et al., 1995). Among workers chronically 
exposed to a hot environment and massive sweating, the prevalence of nephrolithiasis was 
8.5 % while only % of control subjects developed stone disease (Ramello et aI., 2000). 
Also, beach lifeguards and marathon runners have a higher incidence of urinary calculi due 
to chronic dehydration andlor low fluid intake (Parivar et aL ] 996). 
A questionnaire survey was can-ied out by Pin et ai. (1992) to determine the prevalence of 
urinary stone disease in 406 male workers in several occupations. There were 119 quan-y 
drilling and crusher workers (outdoor, physically active), 77 quany truck and loader 
drivers (outdoor, physically inactive), 92 postal deliverymen (outdoor, physically active), 
75 postal clerks (indoor, physically inactive) and 43 hospital maintenance workers (indoor, 
physically active). Urinary stone disease was found to be 5.2 % in outdoor workers 
compared to 0.85 % in indoor workers. Surprisingly, no increased risk of urolithiasis was 
apparent in physically inactive workers. Chronic dehydration was considered to be the 
most important factor for the increased risk of urolithiasis in outdoor workers, and can 
therefore be easily prevented by increased water intake (Pin et aI., 1992). Similar findings 
were obtained by Borghi et al. (1993) who investigated the prevalence of stone disease and 
urinary risk factors in machinists chronically exposed to a hot environment and massive 
sweating. Nephrolithiasis was found in 8.5 % of the entire popUlation of machinists (20 of 
236), while the prevalence on the controls working in normal temperature was 2.4 % (4 of 
165). This study confirmed that chronic dehydration is a real lithogenic risk factor. 
Adequate fluid intake is therefore recommended for individuals working in hot 
environments (Borghi et aI., 1993). 
A recent study by Najem et al. (1997) suggested a possible explanation for idiopathic 
hypercalciuria and nephrolithiasis that involves the role of stressful events in 
simultaneously reducing urinary inhibitors (magnesium, citrate), promoting hyperoxaluria 
and lowering urinary volume. The stressors include those life events that the subjects 
perceived as highly stressful and inflicted upon them an intense emotional impact with 
apprehension and distress for at least one week in duration. Studies of 24-hour urine 
specimens showed that lithogenic urinary constituents (calcium, oxalate and uric acid) 
have peak concentrations within a 24-hour period after an individual is subjected to stress 
(Najem et aI., 1997). Thus stress (work related or otherwise) is a risk factor for stone 
formation. 
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1.2.5 Age 
In children under the age of 15, urinary stone disease shows an initial peak during the first 
two years which reappears at puberty (Reis-Santos, 2000). Bladder stones in children are 
caused by a nutritionally poor diet that is low in animal protein, calcium, and phosphate, 
but high in cereal and is acidogenic (Robertson, 2003). 
Data from epidemiological studies as well as studies based on hospital admittance figures 
have demonstrated that there is a marked increase in stone disease in adults between the 
second and fifth decade of life (Ljunghall et aI., 1975; Robertson et aI., 1979; Ljunghall, 
1987; Reis-Santos, 2000). Recently, some authors have shown a third peak at about 60 
years. 
That advancing age may be a contributing factor to stone disease was examined in a recent 
study by Gergsland et ai. (2002) who found that the urine of healthy young persons (under 
20 years old) vigorously inhibited the growth of calcium oxalate crystals in vitro. Changes 
in serum concentrations of calcium and creatinine with increasing age have indicated 
clinical and metabolic disturbances that may enhance the risk of stone formation (Siener et 
aI., 2000). Renal development from birth to adulthood and the concomitant increase in 
renal concentrating capacity has been shown to increase the risk of crystal1ization in the 
loop of Henle. This coincides with the increasing incidence of calcium oxalate urolithiasis 
(Kok et aI., 1999). It is possible that differences in renal architecture also exit between 
blacks and whites in South Africa. 
1.2.6 Race and Sex 
Idiopathic stone disease occurs more frequently in white caucasians than in blacks, 
irrespective of the geographic area (Ramello et aI., 2000). Brazil has reported a 4-to-1 
caucasian to black ratio between stone formers. In the USA, kidney stone disease is more 
prevalent in whites than blacks (Soucie et aI., 1994). Interestingly, the prevalence of 
nephrolithiasis in black Americans has significantly increased since their conversion to 
caucasian diet (Ramello et aI., 2000). 
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In South Africa, kidney stones occur in 15 % of the white population, whereas it affects 
less than 1 % of the dominant black population (Meyers et aI., 1994). The reason for this 
vast difference in the incidence of renal calculi has yet to be ascertained. Much research 
has gone into investigating urine composition in the two race groups, but results have not 
identified differences which might explain the low stone incidence in blacks (Whalley et 
aI., 1998; Whalley et aI., 1999; Meyers et aL 1994). Dietary differences between the two 
race groups have also been studied (Lewandowski et aI., 2001). It has been suggested that 
the absence of stones in blacks could be due to differences in renal mechanisms for 
handling oxalate in the two race groups (Lewandowski et aI., 2001), or a disparity in the 
presence or absence of promoters and inhibitors of renal stone formation (Whalley et aI., 
1998). Notwithstanding some interesting results, the mystery of the black population's low 
stone incidence has not been resolved. However, attention has recently been focussed on 
the potentially superior inhibitory role of urinary proteins in South African black subjects 
(Craig et aI., 2000; Durrbaum et aI., 2000; Craig et aI., 2001; Durrbaum et aI., 2001; 
Webber et aI., 2003). This is discussed further in paragraphs 1.5.1 and 1.5.4 
Regarding gender, men have both higher stone incidence rates and higher mean urinary 
oxalate concentrations than women (Curhan, 1999). Several investigators have attributed 
the lower incidence of nephrolithiasis in females to their excretion of larger amounts on 
urinary citrate (Shorr et aI., 1942, Hodgkinson et aI., 1962; Welshman et aI., 1976; Menon 
et aI., 1983, Parks et aI., 1986; Hammar et aI., 1987; Trinchieri et aI., 1992). Sex hormones 
have also been shown to be involved in the pathogenesis of calcification: androgens appear 
to increase and estrogens appear to decrease urinary oxalate excretion and kidney calcium 
oxalate deposition (Fan et aI., 1999; Iguchi et aI., 1999; Iguchi et aI., 2000; Heller et aI., 
2002). 
1.3 States of Supersaturation 
The physicochemical theory of stone formation seeks to explain it in terms of the physical 
chemistry of supersaturated solutions, and in terms of the effects of various inhibitors of 
crystal nucleation, growth and aggregation (Rose, 1982). 
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1.3.1 The Fundamental Role of Supersaturation 
The thermodynamic driving force for the change of phase from solution to solid 
(crystallisation) or the reverse (dissolution) is supersaturation. Supersaturation represents 
the excess of free energy between the two phases (Hess et aI., 1996; Kavanagh, 2000). It is 
expressed as the difference in chemical potential of the solution (~soln) and the chemical 
potential of the crystalline phase at equilibrium (~crvst). If ~soln - ~cryst is positive, 
crystallisation occurs and if the difference is negative dissolution will occur. The chemical 
potentials can be expressed in terms of the gas constant (R), the absolute temperature (T) 
and thc activities of the solution (a) and the solution at equilibrium (aeq) (Hess et aI., 1996; 
Kavanagh, 2000). 
L1G = f.lsoln - f.lcryst RTln(aJaeq) 
The fundamental dimensionless driving force for crystallisation is 
L1G = f.lsoln - f.lcryst 
RT 
In(aJaeq) 
(1) 
InS (2) 
S is the dimensionless supersaturation, also called the supersaturation ratio. When S<1 the 
solution is undersaturated. When it is saturated and when S> 1 it is supersaturated. 
Another term used to express the level of saturation is the relative supersaturation (cr), 
where cr = S - 1. Supersaturated solutions are those with cr > 0 (Hess et aI., 1996; 
Kavanagh, 2000). 
1.3.2 Thermodynamics of Crystallisation 
Stone formation is a crystallisation process in supersaturated urine (Hess and Kok, 1996). 
Urinary supersaturation with respect to stone minerals is the driving force for the formation 
of crystal nidus (nucleation) and their transformation to a visible particle (crystal growth) 
(Hess and Kok, 1996; Baumann et aI., 1997). The extent of supersaturation affects the 
kinetics of nucleation, growih, ageing and aggregation which in tum determine crystal size 
distribution (Kavanagh, 2000). Because of the extremely low solubility of calcium 
oxalate, even normal urine is always supersaturated with respect to this salt (Nordin et aI., 
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1993). As such, excretion of small crystals in urine occurs both in healthy individuals and 
in kidney stone formers (Hess et aI., 1996; Fleisch, 1978). Thus, the precipitation of 
calcium oxalate in urine by itself is not a pathological problem as long as the particles 
formed are allowed to pass freely through the urinary tract. Problems occur only if the 
particles are retained and allowed to form the nidus of a stone (Kok et aI., 1994). 
Nucleation 
Urine falls into one of three zones of relative supersaturation (Fig 3, modified from 
Robertson and Nordin, 1973). Urine below the solubility product (S<I) of a given mineral 
is undersaturated with respect to that mineral. Any crystals of the mineral added to it will 
dissolve. 
Urine lying between the solubility product and the formation product (S> 1) of 
homogeneous nucleation, as illustrated in fig 3, is defined as being metastable (Nordin et 
aI., 1993). Urine within the metastable zone may exist for long periods without 
precipitation taking place spontaneously (Robertson et aI., 1982). The closer the urine is to 
the formation product of homogeneous nucleation, the shorter is the latent period before 
crystallisation begins. For a given level of metastable supersaturation, this lag-time may 
be shortened by the presence of nucleating material (such as cell debris, certain 
macromolecules or crystals of other stone-forming salts) in the urine. This process is 
called heterogeneous nucleation (Hess and Kok, 1996). 
Finally, urine which attains or exceeds the formation product of homogeneous nucleation 
is said to be in the labile or unstable zone in which rapid, prolific nucleation takes place 
(Nordin et aI., 1993). Homogeneous nucleation rarely occurs in urine due to the presence 
of many foreign surfaces for heterogeneous nucleation of crystals (Hess and Kok, 1996). 
Urinary supersaturation can be calculated by a special computer program (EQUIL), which 
is based on the chemical analysis of 23 urinary components and the calculation of 103 
complexes (Brovm et aI., 1994). 
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Unstable zone 
Metastable zone 
Undersaturated zone 
CHAPTER 1 
Homogeneous nucleation 
> 
Heterogeneous nucleation 
Induced nucleation 
Crystal growth 
Crystal aggregation 
Formation product 
band 
Solubility product 
Crystal dissolution 
Fig 3: The three main regions of relative supersaturation of urine with respect to a 
sparingly soluble mineral and the crystallisation processes which occur in each 
region (Modifiedfrom Robertson and Nordin, 1973). 
There are two phenomena that are closely related to heterogeneous nucleation - secondary 
nucleation and epitaxy. Secondary nucleation refers to the nucleation of new crystals on 
pre-existing surfaces of their own species, as described above. Epitaxy is the process 
whereby material of one crystal type is precipitated upon the surface of another whose 
lattice dimensions are almost identical (Hess and Kok, 1996). For example, stones from 
recurrent calcium stone-formers contain a larger fraction of calcium phosphate than those 
from single stone-formers. Thus, the calcium oxalate - calcium phosphate epitaxy appears 
to be of clinical significance (Hess and Kok, 1996). 
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Growth 
Crystal growth is the addition of new crystal components onto a crystal nucleus (Hess and 
Kok, 1996). The following differential equation, taken from the review by Gill (1984), can 
be applied to the kinetics of crystallisation: 
dS 
dt 
dP 
dt 
ASll (3) 
where S supersaturation, t = time, P precipitate, = reaction rate constant, A = surface 
area for crystallisation, 11 order of the reaction. For calcium oxalate at low to medium 
super saturations in the metastable range, 11 2. Thus integration of equation (3) becomes 
1 At - (4) 
s 
where So initial supersaturation. By keeping the seed crystal surface area constant in 
metastable supersaturated solutions, the rate constant 0 can be derived with and without 
added inhibitor substances which can then be utilised in the Langmuir adsorption isotherm 
plot to compare inhibitory activities (Gill, 1984). The rate of calcium oxalate 
crystallisation in whole urine can be measured directly by adding specific quantities of 
calcium oxalate seed crystals and measuring changes in either 14C or 45Ca in the 
supernatant and/or precipitated fractions (Gill, 1984). 
Crystal grO\vth in aqueous solution can take place via speciation, bulk diffusion and 
adsorption. Speciation is the binding of monomers to form complexes. Monomers migrate 
through the bulk solution by a process called bulk diffusion and attach to the crystal 
surface by adsorption (Hess and Kok, 1996). 
Aggregation 
Aggregation is the process whereby crystals in solution stick together in order to form a 
larger particle. Crystal aggregation is energetically favoured and thus a natural process. It 
can occur at all states of saturation - undersaturated, saturated and supersaturated 
conditions (Hess and Kok, 1996). 
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Crystal aggregation is considered to be more important for stone formation than crystal 
nucleation and growth. The reason for this. as pointed out in the review by Hess and Kok 
(1996), is that calcium oxalate growth is too slow to produce clinically significant particles 
within the transit time in the urinary tract, whereas aggregation occurs within seconds and 
is thus more dangerous for the fonnation of large crystalline particles in renal tubules. 
Also. ultrastructural analyses of kidney stones reveal a highly aggregated structure (Hess 
and Kok, 1996). 
1.3.3 Mechanism of Stone Formation 
Crystallisation in the urinary tract occurs via three mechanisms nucleation, growth andlor 
aggregation (Gill, 1984; Hess and Kok, 1996). Nucleation is the transformation of solution 
ions into the solid phase. Normal urine is virtually always supersaturated with respect to 
calcium oxalate (Nordin et aI., 1993). Yet, supersaturation with respect to calcium oxalate 
rarely reaches levels required for spontaneous nucleation (or homogeneous nucleation) of 
calcium oxalate crystals. However, crystals may nucleate at lower levels of 
supersaturation in the presence of nucleating sites, a process referred to as heterogeneous 
nucleation (Kavanagh, 2000). Such sites may be provided by cell membranes, proteins or 
by crystals of other types such as apatite and brushite. Heterogeneous nucleation of 
calcium oxalate can be provoked by such stimuli in vitro, and is thought to be a frequent 
event in the process of stone formation, as stones often consist of mixtures of more than 
one type of crystal, as well as membrane fragments and a mixture of proteins (Hess and 
Kok, 1996; Kavanagh. 2000). Unless crystals are retained in the urinary tract, nucleation 
will not lead to stone formation. Crystalluria occurs in normal subjects, but these are 
washed out harmlessly in the urine (Worcester, 1996). If enough nuclei are formed and 
continue to grow unhindered, they will aggregate into larger particles which have a greater 
probability of becoming trapped in the kidney (Worcester, 1996). 
Alternatively, the individual nuclei and aggregates may adhere to membrane walls or be 
deposited within the kidney and continue to grow and aggregate as the supersaturated urine 
flows past until they are too large to pass the kidney (Meyer, 1990). 
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1.4 Naturally Occurring Urinary Inhibitors 
Human unne normally accommodates considerable supersaturations, with multiple 
materials, yet the incidence of renal stones worldwide is less than 1 % (Coe et aL 1991). 
The main reason why stone disease does not occur in all persons is that normal urine 
retards and inhibits crystallisation (Pak et aI., 1976). This observation initiated what came 
to be known as the inhibitor theory of stone formation which states that stones result from 
a deficiency or lack of urinary inhibitors of crystallisation (RyalL 1997). It has provided 
both a possible explanation for the occurrence of stones and a theoretical basis for its 
prevention. If stones form because urine lacks some inhibitor that normally prevents 
crystallisation, further episodes can be prevented by correcting the deficiency with 
medication that has the same inhibitory effects (Ryall, 1997). 
According to Finlayson et ai. (1978), for a substance to be considered as an inhibitor, it 
should hinder the aggregation of individual crystals into larger crystal masses which may 
become large enough to lodge in renal tubules and form the nidus of a stone. 
Alternatively, crystals may bind to specific sites on renal epithelial cells, leading to 
retention and eventual growth into renal stones (Lieske et aI., 1992). An inhibitor should 
interfere ,vith this process and thus diminish the possibility that a crystal will set in motion 
the chain of events that will eventually result in a stone (Worcester, 1996). Also, by 
adsorbing onto the crystal surface, an inhibitor interferes with the formation of the crystal 
lattice and retards the attachment of new ions, thus inhibiting nucleation, and most 
importantly, growth and aggregation into larger crystals, which otherwise would form in 
supersaturated urine (Marangella et al, 2000). 
Some of the protein inhibitors are produced within the nephron, by a process that can be 
triggered or enhanced by the crystals themselves (Marangella et aI., 2000). Therefore, an 
increase in their intra-tubular concentration may be seen as a defence mechanism of the 
kidney against lithogenesis. Anionic inhibitors, by adsorbing onto the crystal surface or 
modifying the crystal structure can prevent adhesion to fixed anionic sites on the tubular 
cells (Marangella et aI., 2000). Based on composition, inhibitors are subdivided into 
micromolecular inhibitors and macromolecular ones; the latter group includes 
glycosaminoglycans (heparin, hyaluronic acid and chondroitin sulphate) and proteins 
(Marangella et aI., 2000). 
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CHAPTER I 
1.4.1 Micromolecular Inhibitors 
Pyrophosphate 
Pyrophosphate occurs in human urine at a concentration of 4 mg/l (March et aI., 2001). It 
has been reported to inhibit hydroxyapatite precipitation in synthetic urine at 
concentrations of 2.87 x 10-6 M (Grases et aI., 2000). Studies have been conducted to 
investigate the effect of pyrophosphate on calcium oxalate crystallisation. It is believed to 
bind to calcium in the solid phase rather than in the solution phase. It also seems to bind to 
calcium oxalate monohydrate and not to the dihydrate (Shirane et aI., 1993). This 
observation is of significance to stone disease because in 70 % of upper urinary tract 
calculi, calcium oxalate monohydrate forms the central core (Gill etaI., 1974; Gill, 1984). 
Results for and against the inhibitory effect of pyrophosphate in whole human urine 
abound (Hallson et aI., 1983; Ryall et aI., 1985; Sidhu et aI., 1986; Baumann et aI., 1989) 
It has been reported that pyrophosphate from stone formers has a reduced inhibitory effect 
on calcium oxalate crystallisation (Conte et aI., 1989). This was attributed to failure ofthe 
renal transformation of orthophosphate into pyrophosphate (Conte et aI., 1989). 
Clinical studies involving the administration of neutral potassium phosphate salt (UroPhos-
K) to stone patients showed that it reduced the urinary saturation of calcium oxalate. In 
addition, by increasing urinary excretion of inhibitors (citrate and pyrophosphate), it 
reduced the propensity for spontaneous nucleation of brushite (the formation product of 
brushite increased) and inhibited crystal aggregation of calcium oxalate (Breslau et aI., 
1995). 
Citrate 
Citrate inhibits calcium oxalate crystal nucleation (Doremus et aI., 1978), growth (Meyer 
et aI., 1975) and aggregation (Ryall et aI., 1981) in aqueous media and inhibits calcium 
oxalate deposition in undiluted (Ryall et aI., 1985) and concentrated (Hallson et aI., 1983) 
unne. Although citrate's inhibitory effect on crystal nucleation and growth can be 
attributed to its complex formation with calcium, it is also known to bind to the calcium 
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oxalate crystal surface, a property that might explain its influence on both crystal growth 
and aggregation. Thus, citrate is both a chelator and crystal poison (Ryall, 1997). 
Based on the above findings, it is not surpnsmg that low unnary citrate excretion 
(hypocitraturia) is an accepted pathogenic factor for calcium renal stone formation 
(Hosking, 1985; Pak, 1991). There are several factors that have been found to modulate 
the urinary excretion rate of citrate. Ingestion of excess animal protein leads to a decrease 
in urinary pH, which in tum lowers urinary citrate (Kok et aI., 1990; Pak, 1991). 
Both scientific and clinical findings indicate that citrate excretion IS a significant 
determinant of stone formation, and citrate supplementation has become an accepted form 
of stone therapy (Ryall, 1997). Indeed, several citrate-containing preparations have been 
successfully used in the management of calcium oxalate nephrolithiasis. These include 
potassium citrate (Pak et at, 1985; Pak et aI., 1986; Whalley et aI., 1996), sodium 
potassium citrate (Schwille et aI., 1985; Schwille et at, 1987; Ogawa, 1994), calcium 
citrate (Sakhaee et aI., 1994; Levine et aI., 1994), calcium-sodium citrate (Schwille, 1997), 
potassium-magnesium citrate (Pak et aI., 1992; Ettinger et aI., 1997) and sodium citrate 
bicarbonate (Allie et aI., 2003). 
Magnesium 
Just like citrate, magnesium has been found to form soluble complexes with oxalate. It has 
been shown to reduce calcium oxalate crystal formation in concentrated human urine 
(Hallson et aI., 1982). This effect was attributed to competition by magnesium with 
calcium for the oxalate ion, leading to the formation of the more soluble magnesium 
oxalate (Hallson et aI., 1982). It is for this reason that magnesium has been labelled an 
inhibitor of calcium oxalate crystallisation (Desmars et aI., 1973). 
Oral administration of magnesium has been found to be successful in the prophylactic 
treatment of urinary stones. In a two year study by Johansson et al. (1980), patients with 
renal stone disease were given a prophylactic treatment containing magnesium hydroxide 
and thereafter the mean stone episode rate monitored and compared to a group of patients 
who only received general advice and no prophylactic treatment. Of the 56 patients who 
received prophylactic treatment over a mInImUm of two years, 45 remained free of 
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recurrences or continued stone growth (total recurrence rate of 12 %). The mean stone 
episode rate during treatment was 0.03 stones per year compared to 0.22 stones per year 
before treatment was instituted. Of the 34 patients who received no prophylactic therapy, 
15 had experienced recurrences after 2 years (44 % recurrence rate). Therefore, in 
comparison, treatment with magnesium hydroxide appeared to reduce the recurrence rate. 
Apart from minor gastrointestinal discomfort no adverse effects were observed during 
treatment (Johansson et aL 1980). 
A recent study (Siener et aI., 1995), has reported that the influence of a magnesium-rich 
vegetarian diet on urinary magnesium concentration and excretion is not as high as 
expected. The oxalic acid content of the plant foods resulted in hyperoxaluria. Stone 
formers are therefore advised to avoid an excess of fruits, vegetables and cereals. These 
observations are in harmony with previous studies that have demonstrated that a balanced 
diet coupled with adequate fluid intake is effective in reducing the risk of calcium oxalate 
stone formation (Hesse et aI., 1993; Goldfarb, 1994; Parivar et aI., 1996; Giannini et aI., 
1999; Massey et aI., 2001). 
1.4.2 Macromolecular Inhibitors 
Kidney stones only develop in the presence of an organic matrix which forms a precisely 
structured framework of the stones. This matrix constitutes on average 1-3 % of the stone 
weight but is spread throughout the entire stone structure (Morse et aI., 1988). The 
association of macromolecules with stones raises the possibility that they playa role in 
their formation (Jones et aI., 1990; Ryall, 2000). These macromolecules are essentially 
glycosaminoglycans GAGs and proteins (Boyce, 1968; Morse et aI., 1988; Ryall et ai., 
2000). 
Glycosaminoglycans (GA Gs) 
Since it was discovered that GAGs - heparin, chondroitin sulphate (ChS) and hyaluronic 
acid (HA) - affected the precipitation of calcium oxalate (Crawford et aI., 1968), several 
tests have been carried out to determine the effects of natural and synthetic GAGs on 
calcium oxalate crystallisation (Wabner et aI., 1991; Yamaguchi et aI., 1993; Shum et aI., 
1993; Shirane et aI., 1995; Senthil et aI., 1996; Chan et aI., 1998). The only GAGs that 
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have been shown to be present in stones are heparan sulphate (Roberts et aI., 1986), and 
hyaluronic acid (Yamaguchi et aI., 1993). Heparan sulphate (HS) has been shown to 
inhibit aggregation of calcium oxalate crystals in inorganic medium (Shirane et aI., 1989), 
enhance calcium oxalate crystal nucleation and inhibit growth in frozen urine (Shum et aI., 
1993). However, it does not affect the urinary metastable limit with respect to calcium 
oxalate or mass deposition of the salt in undiluted, ultrafiltered urine (Suzuki et aI., 1996). 
Nevertheless, these findings for HS suggest that it may playa role in inhibiting calcium 
oxalate crystallisation. ChS, the most prominent urinary GAG (Roberts, 1986) has not 
been detected in stones and heparin does not exist in human urine (Ryall, 1997). 
Proteins 
Proteins are a highly diversified class of biomolecules. Differences in their chemical 
properties, such as charge, organic functional groups, shape, size and solubility enable 
them to perform many biological functions. These functions include enzyme catalysis, 
metabolic regulation, binding and transport of small molecules, gene regulation, 
immunological defence and cell structure (Stryer, 1995). 
Proteins whose inhibitory effects on calcium oxalate crystallisation have been determined 
in either inorganic reaction solutions or undiluted urine include albumin (Edyvane et aI., 
1986; Ryall et aI., 1991; Dussol et aI., 1995; Grover et aI., 1998), Tamm-HorsfaIl 
glycoprotein - THG (Hess et aI., 1989; Hess, 1992; Hess, 1994), uropontin (Shiraga et aI., 
1992; Worcester, 1992; Worcester et aI., 1995; Worcester et aI., 1996), nephrocalcin 
(Nakagawa et aI., 1983; Coe et aI., 1991; Chang et aI., 2001), inter a-trypsin inhibitor 
(Sorenson et aI., 1990; Atmani et aI., 1993; Dawson et aI., 1998; Moriyama et aI., 2001) 
and urinary prothrombin fragment 1 or UPTFI (Ryall et aI., 1995; Ryall et aI., 1997; 
Durrbaum et aI., 2000; Webber et aI., 2003). Besides THG which can inhibit or promote 
calcium oxalate crystallisation depending on experimental conditions (Grover et aI., 1990; 
Hess, 1992; Hess, 1994), the other proteins listed above have been shown to inhibit the 
nucleation, growth or aggregation of calcium oxalate crystals, and have accordingly been 
credited with performing some function in the formation of calcium oxalate stones (Grover 
et aI., 1998). However, because the effects of these proteins have been tested individually 
using different techniques, it is impossible to assess their relative contributions to the 
crystallisation of calcium oxalate in vivo, and consequently their possible influence on 
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stone fonnation (Grover et aI., 1998). The proteins mentioned above will be discussed in 
detail in the section below. 
1.5 Urinary Proteins and Kidney Stones 
Tile Organic Matrix 
What researchers in stone disease know for sure about the organic matrix is that it is a 
universal component of all human renal calculi which accounts for some 2-5 % by weight 
of most stones (Boyce et aI., 1956). An in-depth study of the structure of the organic 
matrix of human urinary concretions by Boyce (1968) showed that it is a heterogeneous 
material composed of 64 % protein, 9 % non-amino sugars, 5 % glucosamine, 10 % bound 
water and 12 % organic ash (Boyce, 1968). According to this author, the adsorption of 
macromolecules onto the surface of crystals is a selective process that is necessary for 
stone fonnation. As such, matrix deposition may be the differentiating factor between 
stone fonners and healthy people. The fact that the matrix is largely composed of 
different proteins is an indication that they play some role in stone pathogenesis. What 
though is their source? Nucleation and early gro-vvth of calcium oxalate crystals within 
renal tubules results in the incorporation of normal urinary organic components (Finlayson 
et aI., 1961; Khan et aI., 1987). This is the first type of matrix. Once the crystal aggregate 
becomes lodged in the renal tubule, trauma resulting from abrasion of the urothelial lining 
will change the macromolecular composition of the urine bathing the crystals and will 
result in the deposition of a second type of matrix which is chemically different from that 
occluded in crystals during nucleation and early growth (Doyle et aI., 1991). Evidence 
supporting this is the presence in stones of serum proteins which are too large for 
glomerular filtration (Boyce et a1., 1962), lipids a very nominal component of urine 
(Khan et aI., 1988), erythrocytes, mitochondrial ghosts and bacteria (Finlayson et aI., 
1984). 
Proteins detected in calcium oxalate stones include Tamm-Horsfall glycoprotein (THG), 
albumin, a- and y-globulins, haemoglobin, neutrophil elastase, transferrin, a)-
microglobulin, CD59 protein (protectin), superoxide dismutase, aI-antitrypsin, uropontin 
(osteopontin), nephrocalcin, ~2-microglobulin, aI-acid glycoprotein, renal lithostathine, 
urinary prothrombin fragment 1 (UPTFl) and inter a-trypsin inhibitor (Ryall, 1996). One 
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approach to identifying possible functions for proteins in stone formation is to examine 
their individual effects on calcium oxalate crystallisation. This has been attempted for 
relatively few stone proteins. The next few paragraphs will discuss results obtained thus 
far on THG, nephrocalcin, uropontin (osteopontin), urinary prothrombin fragment I 
(UPTFl), uronic acid-rich protein (inter-a-trypsin inhibitor, bikunin) and albumin. 
1.5.1 Tamm-Horsfall Glycoprotein (THG) 
THG is an acidic urinary glycoprotein with a monomeric molecular weight of 80 000 
daltons or 80 kDa (Ryall, 1997) that is synthesised and secreted by epithelial cells in the 
thick ascending limb of the loop of Henle, and early distal convoluted tubule (Kumar et aI., 
1990). 20-200 mg of protein is excreted in urine each day (Hunt et aI., 1994). THO has 
been found to exhibit different effects on calcium oxalate crystallisation depending on 
ambient conditions and methodology. Under conditions of high ionic strength and low pH, 
it self-aggregates (Hess et aI., 1989; Hess, 1992; Hess, 1994). Elevated concentrations of 
THO itself also favour self-aggregation. The state of aggregation influences whether THO 
will inhibit or promote crystallisation (McQueen et aI., 1966; Hess, 1994). THG only has a 
minor effect on crystal growth (Hess, 1994). It has little effect on calcium oxalate 
nucleation, although it appears to promote crystal nucleation at very high ionic strength 
and low pH (Hess, 1994). All the same, it is a potent inhibitor of calcium oxalate crystal 
aggregation in undiluted, ultrafiltered urine (Ryall et aI., 1991). This property results from 
steric hindrance and not from adsorption onto the crystal surface (Ryall et aI., 1991). A 
study by Hess and associates (1989) using a spectrophotometric assay demonstrated that 
THG is a strong inhibitor of crystal aggregation in a concentration-dependent manner, 
inhibiting aggregation by 50 % at concentrations of 10.8 molll and nearly 90 % at 5 x 10.8 
molll. However, increases in the ionic strength of the assay solution (from, 0.1 to 0.28) or 
decreases in pH (from 7.2 to 5.7) greatly diminished the inhibitory activity of THO. This 
decrease in inhibitory activity was directly related to an increase in viscosity of THO in 
solution caused by self-aggregation (Hess et aI., 1989). Thus, conditions of ionic strength 
and pH that may be seen in urine can lead to highly polymerised THG that fails to inhibit 
crystal aggregation and may even promote aggregation in certain situations (Worcester, 
1996). 
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Recently, THG has been isolated from the urine of South Africa's stone free black and 
stone prone white populations and has been tested in various crystallisation experiments 
(Craig et aL, 2000; Craig et aL, 2001). Several interesting results have been found. THG 
isolated from blacks (BTHG) was found to be a more potent inhibitor of COM crystal 
aggregation than that from whites (WTHG) (Craig et aI., 2001). It was therefore 
speculated that perhaps the relative immunity of the black population to calcium oxalate 
stone formation might be linked to the more potent activity of this race group's THG in 
inhibiting aggregation. Various techniques have been used to characterise the biochemical 
properties ofTHG from normal and stone-forming black and white South Africans. These 
include matrix assisted laser desorption ionisation time of flight mass spectrometry 
(MALDI-TOF), amino acid analysis and tryptic finger printing digestion (Craig et a1., 
2000). No compositional or structural differences were found (Craig et a1., 2000). 
1.5.2 Nephrocalcin 
Nephrocalcin (NC) is produced in the epithelium of the proximal tubules and thick 
ascending limp of the loop of Henle (Nakagawa et aI., 1990). It has a monomeric 
molecular weight of 14 kDa, although the protein can self-associate into larger aggregates 
(Nakagawa et aI., 1990; Mustafi et al., 1996; Worcester, 1996). NC contains y-
carboxyglutaminc acid or Gla (glycosylated) and considerable numbers of phosphate 
residues (phosphorylated), therefore its net charge is strongly anionic (Coe et aL, 1991). 
Nakagawa et al (1985) reported that NC has the ability to form stable films at air-water 
interfaces with a high collapse pressure. They attributed this to NC's amphiphilic structure 
- it has hydrophilic and hydrophobic regions. This feature may depend on the presence of 
Gla (Coe et a1., 1991; Chang et aI., 2001). 
Hydrophilic regions would possess an affinity for the charged crystal surface, whereas the 
hydrophobic surface would be oriented toward the solution, offering solution ions a poor 
surface for lodging, thus discouraging overgrowths of new crystals over the protein coating 
(Coe et a1., 1991). This asymmetry is a crucial property of an inhibitor because as these 
authors pointed out, in a radially symmetrical inhibitor, there will be a fixed and stable 
array of charged sites on all sides - like the bristles on a cylindrical hair brush. The 
charged regions that attach to the crystals would be mirrored on the solution side by an 
exact replica that solution ions would recognise and bind to just as the protein bound to the 
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crystal, offering to ions an ideal surface for heterogeneous nucleation. Kidney tubules 
provide a constant flow of new ions, so crystals at a collecting duct, for example would be 
constantly bathed by a solution with ions that are constantly being replenished, and could 
grow at leisure if not covered by a film that inhibited grO\vth (Coe et al., 1991). 
In vitro experiments show that NC can inhibit the growth of calcium oxalate crystals in 
metastably supersaturated calcium oxalate solutions (Nakagawa et al., 1983; Chang et al., 
2001). The addition of increasing amounts of NC to the solution causes progressive 
growth inhibition. Growth inhibition requires NC concentrations of 10-6 to 10-8 molll, 
similar to those found in urine (Nakagawa et al., 1983). NC's ability to inhibit groVvih is 
related to its ability to bind to a crystal's surface, where it blocks growth sites in the crystal 
lattice structure (Nakagawa et al., 1983). When calcium oxalate crystals are incubated in 
solutions of NC and adherence of the protein to crystal surface is measured with anti-NC 
antibody, directly measured adsorption increases in parallel with inhibition (Worcester et 
al., 1988). Other data (Deganello, 1991) suggest that NC binds in a preferential manner to 
certain crystal faces and blocks growth of the crystal along those planes. NC can also 
inhibit calcium oxalate crystal nucleation (Asplin et al., 1991). When a few large well-
formed crystals of calcium oxalate were incubated in a metastably supersaturated solution 
of calcium oxalate, nucleation of new crystals occurred at the crystal surface, whereas 
growth of the original crystals accounted for only a negligible amount of loss of solute 
from the solution (AspEn et al., 1991). Addition of 5 x 10-7 molll NC to the solution 
prevented formation of new crystals. Thus, concentrations ofNe similar to those found in 
urine can prevent calcium oxalate crystal nucleation in vitro (Asplin et al., 1991). NC has 
been found to exert inhibitory effects on calcium oxalate crystal aggregation. Aggregation 
inhibition was studied in vitro (Hess et al., 1989) using a spectrophotometric assay in 
which calcium oxalate crystals were suspended in a solution that was just saturated with 
respect to calcium and oxalate. NC was found to be a potent aggregation inhibitor at all 
concentrations above 5 x 10-7 moili. At that concentration, aggregation was inhibited by 
80% (Hess et aL, 1989). NC isolated from urine of calcium stone formers has been found 
to have structural abnormalities, which reduce growth inhibition efficiency and 
amphiphilicity (Nakagawa, 1997). The defects in stone formers possibly arises from a 
single primary sequence abnormality that prevents proper golgi apparatus processing for 
Gla, and also affects calcium binding sites needed to form crystal surface attachment (Coe 
etal.,1991). 
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1.5.3 Uropontin (Osteopontin) 
Uropontin has been isolated from human urine and has been found to inhibit calcium 
oxalate crystal grovvth (Worcester, 1992). Its N-terminal sequence is identical to that of 
osteopontin, a protein that is found in bone matrix, produced by osteoblasts (Butler, 1989). 
The polypeptide backbone has a molecular weight of 32 kDa. The bone-derived and 
renally derived forms appear to be very similar with respect to amino acid sequence, and 
are presumably products of the same gene, but may differ in their post-translational 
modifications, such as glycosylation, phosporylation and sulphation (Negata et aI., 1989; 
Hoyer. 1994). It is rich in aspartic acid, and has a conserved sequence of 8-10 aSPaItic acid 
residues in the N-terminal portion of the protein (Worcester, 1996). Uropontin 
(osteopontin) can inhibit both spontaneous nucleation (Worcester et aI., 1995), growth 
(Worcester et aI., 1992) and aggregation (Asplin et aI., 1995) of calcium oxalate crystals in 
supersaturated solutions. 
When crystals nucleate in supersaturated solutions of calcium oxalate in the absence of the 
protein. the crystal habit produced is calcium oxalate monohydrate (COM). However, in 
urine the crystals found are predominantly calcium oxalate dihydrate (COD) (Elliot et aI., 
1980). This is especially true in normal subjects; in stone formers with crystalluria, COM 
crystals are seen with increased frequency (Elliot et aI., 1980). Addition of several 
inhibitory macromolecules to supersaturated solutions, including polyaspartic acid and 
osteopontin purified from cell culture, promotes the formation of COD in preference to 
COM (Wesson et aI., 1995). This may be of significance because additional studies 
suggest that COD crystals have a lower affinity for renal papillary cell membranes than do 
COM crystals (Wesson et aI., 1995). Thus, another role of urinary inhibitors such as 
uropontin might be to favour formation of COD crystals over COM in supersaturated 
solutions, which might be less likely to bind to renal epithelial cells and be retained in the 
kidney (Worcester; 1996). Indeed, it has recently been demonstrated (Lieske et aI., 1995) 
that uropontin (osteopontin) inhibits the adhesion of COM crystals to renal epithelial cells 
in culture. 
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1.5.4 Urinary Prothrombin Fragmellt 1 (UPTF1) 
Studies of calcium oxalate crystals freshly precipitated in urine, revealed a protein present 
in significant quantities but which could not be detected in normal urine (Doyle et a1.. 
1991 ). Amino acid sequencing revealed that this protein had N -terminal homology with 
human prothrombin (Stapleton et aI., 1993). Further study showed that the protein was a 
urinary form of the F 1 activation peptide of prothrombin and it was therefore called urinary 
prothrombin fragment 1 (UPTF 1). It is a glycoprotein with a molecular mass of 31 kDa 
(Stapleton et aI., 1995). It is located specifically in the human kidney in the thick 
ascending limb of the loops of Henle and the distal convoluted tubules, where it is present 
in greater quantities in stone formers compared to healthy controls (Stapleton et aI., 1993). 
UPTFI is a potent inhibitor of both calcium oxalate crystal grmvth and aggregation in 
undiluted, ultrafiltered human urine (Ryall et aI., 1995), a property that is attributed to its 
ten Gla residues located in the N-terminal region of the molecule (Ryall, 1997). It has 
therefore been suggested that variations in the amount of the protein excreted in urine, or 
alterations in its molecular structure, may possibly predispose some individuals to 
urolithiasis (Ryall, 1997). However, more investigation is required to confirm the role of 
this protein in providing protection from stone formation. 
Like THG, UPTFI has recently been investigated in the black and white populations in 
South Africa (Durrbaum et aI., 2000; Durrbaum et aI., 2001; Webber et aI., 2003). Here 
too, important results have been found. The in vitro inhibitory effects of UPTFI isolated 
from urine of healthy black (BF1) and white (WF1) subjects have been studied on calcium 
oxalate crystallisation using a "cross-over" design in which each protein was tested for its 
effect in its own endogenous urine as well as in the urine obtained from the other race 
group (Durrbaum et aI., 2001). BFl was found to be a superior inhibitor compared to 
WFl, but more interestingly, the urine from black subjects induced a more powerful 
inhibitory effect from both proteins relative to urine from white subjects (Durrbaum et aI., 
2001). Biochemical characterisation of UPTFI from the two race groups has ShO\\-11 no 
differences in molecular weight or amino acid sequence and composition (Durrbaum et aI., 
2001). 
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In another study, the amount of UPTFI trapped in crystals formed in urine from the two 
races was compared (Webber et 31., 2003). Crystals from the black and white groups' 
control samples were composed mainly of calcium oxalate monohydrate (COM) and 
calcium oxalate dihydrate (COD) respectively. Pure COM and COD were prepared from 
both race groups' urine by adjustment of the calcium concentration to 0.5 and 12 mM 
respectively. A significant amount of UPTFI was included in COM with undetectable 
amounts in COD crystals. The black group's COM crystals were found to contain more 
UPTFI per milligram of calcium oxalate than those of the white group. The authors 
concluded that the composition of black subjects' urine is more favourable for UPTFl's 
binding than urine from whites. It was therefore inferred that the greater amount of 
intracrystalline UPTF 1 from the black group may promote the dismantling of crystals by 
the action of urinary proteases and thus playa protective role (Webber et aL, 2003). 
1.5.5 Uronic-Acid-Rich Protein (Inter-a-trypsin-Inhibitor, Bikunin) 
Inter-a-trypsin-inhibitor (IT!) was first isolated in urme m 1990 by Sorenson and 
colleagues, and was found to be an inhibitor of calcium oxalate growth in inorganic 
medium (Sorenson et aL, 1990). It comprises three protein chains linked by chondroitin 
sulphate: two heavy chains HI and H2 and a light chain most commonly known as 
bikunin. The physiological function of the two heavy chains is unknown; neither have 
they been found in urine (Dawson et aL, 1998). The protein, derived from the urine of 
stone formers has been shown to have a reduced inhibitory effect on calcium oxalate 
crystallisation as compared to that of healthy subjects (Atmani et al., 1994). 
A similar protein has been isolated in rat urine (Atmani et aL, 1995). Like its human 
counterpart, it cross-reacted with anti-ITI, this suggested that it belonged to the ITI super 
family, as does a 35 kDa urinary protein (Tang et aL, 1995) with N-terminal sequence 
identical to bikunin, the light chain of ITI. Evidence suggests that all of these proteins are 
one and the same bikunin. This supposition is supported by the recent demonstration that 
uronic-acid-rich protein is actually bikunin (Atmani et aL, 1996). 
Bikunin inhibits calcium oxalate crystal nucleation and growth (Atmani et aL, 1999) in 
inorganic systems and is present in calcium oxalate crystals precipitated from urine 
(Atmani et aL, 1996). It has been found to inhibit COM crystal adhesion to renal tubular 
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cells (Ebisono et al., 1999). It may therefore contribute to the regulation of crystal 
adhesion and retention within tubules during stone formation (Ebisono et aI., 1999). 
Hyperoxaluria and renal calcium oxalate crystal deposition in rat models result in the 
increased expression of crystallisation inhibitors, such as inter-alpha-inhibitor related 
proteins (Moriyama et al., 2001). Thus, the kidneys respond to nephrolithic challenges by 
producing proteins, such as bikunin, that inhibit crystal formation and retention (Moriyama 
et a1.. 2001). 
Bikunin isolated from urine of renal stone formers is de-glycosylated and has an inferior 
inhibitory effect on calcium oxalate crystal growth compared to protein from healthy 
subjects (Suzuki et aI., 2001). Also, since stone fonners produce a higher concentration of 
the protein, it would appear that its effect on the pathogenesis of urolithiasis is linked to its 
concentration and degree of glycosylation. 
1.5.6 Albumin 
After THG, albumin is the most abundant protein in urine (Grover et a1., 1998). The 
presence of albumin in the organic matrix of kidney stones suggests that it may playa role 
in nephrolithiasis (Morse et aI., 1988). 
A matrix profile was recently obtained by SDS gel electrophoresis of the pooled EDT A 
extracts of five different kidney stones (Dussol et aI., 1995). It featured albumin as the 
major component of the stone matrix and proposed that albumin is the protein that binds 
most other proteins to form the matrix of all stones. This study had some severe 
limitations which were pointed out by Binnette and co-workers (1996). Firstly, in order to 
gather enough material to study, pooled stone extracts were used, thus excluding the 
possibility of detecting individual variations in composition. Also, by using SDS gel 
electrophoresis they may have failed to detect differences in protein composition which 
could have been revealed by 2-D gel electrophoresis. In addition, no mention was made of 
a residue after extraction. Previously, researchers had discovered that dialysis against 
EDTA-containing solutions removed most of the crystallising component of the stones, 
leaving a residue which proved difficult to solubilise. Finally, proteins considered by other 
investigators (Grover et aI., 1998) as major components of matrix were not reported 
(Binette et a1., 1996). 
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The effects of albumin on calcium oxalate crystallisation in inorganic solution (Hess; 
1989), undiluted ultrafiltered urine (Edyvane et aI., 1987; Ryall et aI., 1991) as well as in 
whole urine (Edyvane et aI., 1987; Cerini 1999) have been determined. Many researchers 
have reported that it is an inhibitor of calcium oxalate aggregation (Edyvane et aI., 1987; 
Worcester, 1996; Grover, ] 998). It has also been shown that albumin reduces the size of 
crystal aggregates and causes a small increase in the amount of crystal matter precipitated 
(Edyvane et al., 1987; Ryall et aI., 1991). Albumin inhibits calcium oxalate monohydrate 
aggregation detectably at 0.01 JIM which is near its normal urinary concentration (Hess et 
al., 1989). The reduction in size of crystal aggregates caused by albumin has been 
measured at 32 % of the initial value - 5.9nm versus 8.6nm (Grover et aL, 1998). At 
concentrations of 0.005 % to 0.10 % (v/v), it has no effect on the metastable limit of urine 
as detected by Coulter Counter (Edyvane et aL, 1987). However, it caused a marked 
increase in the number and volume of calcium oxalate crystals deposited in response to an 
oxalate load. Analysis of particle size distributions showed that the crystals deposited in 
the presence of albumin were smaller than those occurring in the controL This apparent 
promotion effect is due to its inhibition of crystal aggregation which increases the crystal 
surface area available for calcium oxalate deposition (Edyvane et al., 1987). 
Albumin's effect on calcium oxalate growth has been described as modest or absent 
depending on experimental conditions. In a dilute seeded crystallisation system, albumin 
was found to be a weak inhibitor of crystal growth (Edyvane et al., 1987). Worcester et aL 
(1988) reported that albumin has a strong affinity for COM crystals, yet did not inhibit 
crystal gro\\;th at even 3 x 10-6 M. They therefore proposed that either almost all of the 
adsorption occurred at non-growth sites or the protein adsorbed to growth sites but did not 
prevent growth (Worcester et al., 1988). Similar results were obtained by Grover and 
associates (1998) who found that crystal growth, as measured by [14C]-oxalate 
disappearance was unaffected by HSA. Other investigators have found HSA to display 
significant affinity for COM crystals (Worcester et al., 1988; Dussol et al., 1995). 
Edyvane et al. (1987) noted that albumin increased the volume and number of calcium 
oxalate crystals precipitated from whole urine. They also reported that the crystals 
deposited in the presence of albumin were smaller than those occurring in the control. In a 
more recent study by Cerini et al. (1999) it was demonstrated that albumin purified by 
immunoaffinity chromatography from the urine of healthy subjects was a more potent 
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nucleator of calcium oxalate than commercial serum albumin. Nucleation was evaluated 
by the number of crystals generated from a metastable calcium oxalate solution in 
polystyrene wells coated with albumin which had been derived from healthy subjects and 
idiopathic calcium stone formers. Also, calcium oxalate crystals induced by albumin from 
healthy subjects was significantly more numerous than albumin from idiopathic calcium 
stone formers. Cerini and co-workers have pointed out that, at first sight, promotion of 
nucleation could be considered unfavourable because one would assume that keeping the 
number of calcium oxalate crystals formed in primitive urine to a minimum would 
facilitate the control of their gro\\tth by specific inhibitors. However, they argued that 
increasing the number of crystal nuclei would be beneficial because it would decrease 
calcium oxalate saturation, thus limiting the size that crystals could reach and favouring 
their elimination by urine flow. The fact that healthy subjects have significantly smaller 
crystals in their urine than stone formers supports this (Cerini et aI., 1999). 
Prompted by the above observation, Chen et al. (2001) investigated the overall effect of 
albumin on calcium oxalate crystallisation. At a concentration of 100nM albumin was 
found to promote nucleation by 8.9 % relative to the control. Inhibition of crystal growih 
was determined using the spectrophotometric assay developed by Asplin and associates 
(1997). Albumin exerted an inhibitory effect on crystal growth, with ICso obtained from 
regression analysis being 37.5 nM. Finally, at a concentration of 100 nM, albumin exerted 
an inhibitory effect of 72.73 % on crystal aggregation. Thus, the overall effect of albumin 
on calcium oxalate crystallisation may be as an inhibitor (Chen et aI., 2001). Their results 
were compatible with those of Cerini and co-workers mentioned above. 
Another approach to establishing the association of proteins with crystals is to study them 
in calcium oxalate crystals freshly precipitated from healthy human urine since they will 
not contain proteins that are released secondarily due to tissue damage (Finlayson et aI., 
1961; Khan et aL, 1987; Morse et aI., 1988; Morse et aI., 1989; Doyle et aI., 1991). A 
major finding of these studies is that inclusion of proteins into crystals is a selective 
phenomenon (Doyleet aI., 1991; Doyle et aI., 1995). However, THG and albumin, the 
most abundant proteins found in urine were not detected in the crystal matrix. It was 
demonstrated that the major protein associated with urinary crystals is UPTFI (Doyle et 
aI., 1991; Ryall, 1997). Nevertheless, in these earlier studies, human urine samples were 
centrifuged and filtered before inducing crystallisation. Atmani et al. (1996) later 
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discovered that these procedures contributed to the loss of a significant portion of the 
urinary macromolecules and that experiments should be conducted in whole human urine 
without prior centrifugation and filtration. Another significant outcome of their study was 
that not only prothromnin-related proteins but also albumin and particularly osteopontin 
are associated with calcium oxalate crystals formed in human urine provided the crystals 
are washed only with distilled water and not with NaOH. Perhaps these proteins were not 
tightly bound to the crystals and were removed easily by washing with a strong agent such 
as NaOH. They proposed that the presence of these proteins in crystal matrix may not be 
as selective as previously reported. Their presence may indicate that they are involved in 
modulating crystallisation either indirectly or in concert with each other to give a resultant 
effect (Atmani et aL 1996). 
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1.6 Objectives 
The presence of stone free and stone prone populations in South Africa presents a unique 
research opportunity to investigate the pathogenesis of this disease. The kidney stone 
research group at the University of Cape Town (of which the present investigator is a 
member), has recently been studying the role of urinary proteins in this context. Indeed, 
results for Tamm-Horsfall protein and urinary prothrombin fragment 1 have already been 
described earlier in this chapter. The project described in this thesis undertook to extend 
these investigations to the urinary protein, albumin. This protein was selected on the basis 
of its reported inhibition of calcium oxalate aggregation which is widely regarded as the 
key crystallisation mechanism in kidney stone fonnation. 
The objectives of this study were therefore: 
(1) to isolate and purify albumin from the urine of healthy black and healthy white male 
subjects; 
(2) to test and compare the effects of the protein from each race group, as well as that of 
commercial human serum albumin on the kinetics of calcium oxalate crystallisation; 
(3) to measure the zeta potentials of calcium oxalate monohydrate crystal slurries which 
have been coated with these proteins; 
(4) to measure the degree of aggregation inhibition effected by these proteins on calcium 
oxalate monohydrate crystal slurries in sedimentation experiments; 
(5) to test and compare the effect of these proteins on the volume-size distribution of 
calcium oxalate crystals in in vitro crystallisation experiments; 
(6) to test and compare the effects of these proteins on calcium oxalate crystal deposition 
rates using labelled [,4C]-oxalate. 
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CHAPTER 2 
CHAPTER 2: ISOLATION, PURIFICATION AND 
VERIFICATION OF URINARY ALBUMIN 
2.1 Introduction 
Albumin is one of the most abundant proteins in urine. Normal levels of urinary albumin 
are approximately 5 - 30 mg!l for a 24 hr urine sample (Rulm et aI., 1994). Using 
concentrated urine samples, Cerini and co-workers (1999) reported that on average, 
albumin excretion in healthy subjects is about 2.40 mgl24hr. However, the distribution in 
individuals covered a wide range (0.192 to 21.8 mg!24hr) (Cerini et aI., 1999). This 
observation has been confirmed by other investigators and is due to the state of hydration 
of the body. The volume of urine excreted can be highly variable depending mainly on the 
individual's fluid intake and physical activity. In dilute urine, the total protein excretion 
may be underestimated. If the urine is concentrated, as frequently occurs after strenuous 
physical activity, an increased protein concentration could be misinterpreted (Newman et 
aI., 2000). 
Several different approaches have been used for the isolation of urinary albumin. These 
include diethylaminoethyl (DEAE)-cellulose column chromatography (Hess et aI., 1989); 
high-performance liquid chromatography (Dussol et aI., 1995); immunoaffinity 
chromatography (Cerini et aI., 1999); and high-performance immunoaffinity 
chromatography and flow injection analysis (Ruhn et aI., 1994). These methods rely on 
the pre-treatment of urine. In the present study two approaches of sample preparation were 
used. 
The first method of sample preparation used was developed by Cerini et aI. (1999) and 
describes the preparation of concentrated urine samples. Briefly, urine samples were 
ultrafiltered using an Amicon hollow fibre bundle (HIP 10) with a nominal cut-off of 10 
kDa relative molecular mass. The concentrate was extensively dialysed in distilled water 
until most of the pigment was removed, and then lyophilised. Lyophilised samples were 
resuspended in PBS and albumin isolated from this mixture by immunoaffinity 
chromatography. 
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The second method of sample preparation used was to grow calcium oxalate crystals in 
whole urine as described by Atmani et al. (2002), and then demineralise the crystals in 
EDT A. Inorganic impurities were then removed by dialysis. This method yielded a 
pigment free protein extract from which albumin was isolated by immunoaffinity 
chromato graphy. 
Immunoaffinity chromatography was selected for the isolation of albumin in this study 
because previous work had shown that it is a relatively quick and efficient approach 
(Cerini et aI., 1999). It is a molecular technique which can be used to isolate antibodies, 
antigens, hormones or other proteins by taking advantage of their binding affinity for their 
respective ligands. The desired protein is isolated from a crude extract through its specific 
binding to an antibody that has been coupled to a gel matrix. By changing column 
conditions, the analyte can be eluted for quantification or collected for further use (Ruhn et 
aI., 1994). The procedure can be divided into 3 steps as illustrated in Fig 4. 
The first step involves the binding of the ligand (antibody) to the sepharose matrix to form 
a ligand-matrix complex, which is packed into a column. Next, a crude extract is passed 
through the column and the ligand's recognized substrate binds to the ligand-matrix 
complex, halting its passage through the geL Unbound impurities are removed from the 
gel column using a strong wash of high ionic strength. Finally, a stronger more acidic 
second wash is used to elute the desired protein. This second wash relies on the reversible 
binding properties of the ligand, which allows the bound protein to dissociate from its 
ligand in the presence of this stronger wash (Ruhn et aI., 1994). 
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Fig 4: Steps for affinity chromatography. Top panel: bonding of ligand to sepharose matrix 
results in immobilised ligand-matrix complex. Middle panel: sample mixture is added to gel 
column. Complimentary proteins bind to ligand-matrix complex. while the non-binding impurities 
are washed out. Bottom panel: to remove the bound proteins and retrieve them from the gel. a 
stronger second wash is run through the column and the desired protein is washed out. (Figure 
taken from http://ntri.tamuk.edulfplclpursammat.html). 
In this study two different matrices for the isolation of urinary albumin were used. The 
first matrix was CNBr-activated sepharose to which anti-human albumin (anti-HA) was 
coupled directly. This has the advantage of being very specific and having low 
background. The disadvantage is lower binding capacity, as the orientation of the antibody 
coupled to the CNBr matrix is not optimal for albumin binding, because coupling of the 
antibody to the matrix is through free amine groups. Repeated use of the column also leads 
to loss of antibody from the column. 
To circumvent this problem, a second approach was employed In which anti-HA was 
cross-linked to protein-G sepharose beads. Protein-G is a cell wall protein of certain 
pathogenic bacteria which specifically binds to the Fc region of the immunoglobulin or 
antibody (Sjobring et aI., 1989). This ensures that both binding sites on the 
immunoglobulin are available to bind to albumin (Fig 5). Thus, protein-G sepharose has a 
much better binding efficiency since it orientates the anti-HA for optimal binding to human 
serum albumin (HSA). 
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Active Sites 
Light chain 
+ 
Heav)' chain 
Fig 5: Mechanism of binding of Protein-G to an antibody. (Figure 
modified from www.bch.bris.ae. ukistafJIhenersonllmmunoglobulins2. hIm) 
2.2 Method 
2.2.1 Urine Collection and Sample Preparation 
Preparation of Concentrated Urine Samples 
24 hour urine samples were collected from 20 healthy black and 20 healthy white subjects 
in 2 I plastic bottles containing 10.0 g of boric acid, to prevent calcium oxalate 
precipitation. The absence of blood and infection from individual urine samples was 
confinned using urinalysis test strips (Combur 10 test strips; Boehringer Mannheim). 
Individual urine samples were filtered with a pre-filter (Macherey-Nagel) , followed by a 
0.420 pm Millipore filter (Millipore Corporation, Bedford), and then pooled. Pooled 
samples from each race group were ultra-filtered using an Amicon hollow fibre bundle 
(H 1 P 10) with a nominal cut-off at 10 kDa relative molecular mass. The concentrate was 
dialysed extensively for two days in distilled water at 4 DC with two changes of 20 I of 
distilled water for every 500 ml of concentrated urine. The dialysate was then lyophilised. 
Lyophilised samples from black and white subjects were resuspended in 280 ml and 240 
ml of PBS respectively. Albumin was isolated from these samples using the CNBr - anti-
HA sepharose column. 
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Preparation of Crystal Matrix Extract 
CaOx crystallisation 
Preparation of urine for the isolation of albumin by protein-G sepharose was carried out as 
follows. 24-hour urine specimens were collected from 2 healthy black and 7 healthy white 
male subjects and tested for blood and infection as described above, and then pooled. (The 
number of white subjects used was greater than the number of black subjects because 
CaOx crystals induced in urines from the former group were required for the optimisation 
experiments described in the demineralisation paragraph below). An adapted method of 
that reported by Atmani et al. (2002) was used for the induction of calcium oxalate 
crystallisation in whole urine. Pooled urines from the race groups were warmed to 37.0 °c 
in a shaking water-bath. CaOx crystallisation was induced by drop-wise addition of 15.0 
mIll of 100 mM sodium oxalate solution at pH 5.9 - 6.5. After 1 hour, the same amount of 
sodium oxalate was added to the mixture. An hour later, the crystals were harvested by 
centrifugation at 8000 g using a JR-20 rotor (Beckman Instruments, Fullerton, Calif. USA) 
for 30 min at room temperature. 
Demineralisation 
Preliminary experiments demonstrated that the volume of EDT A used in demineralising 
the CaOx crystals had an effect on the amount of dissolved albumin. It was therefore 
necessary to optimise the demineralisation process by dissolving 1.14 g of crystals formed 
in urine from white subjects, in different volumes of EDTA. The optimum volume was 
found to be 10.0 ml. 
Crystals formed in urine from black and white subjects were demineralised in 10.0 ml 250 
mM EDT A, pH 8, per gram of crystals for three days with continuous stirring at 4°C. The 
supernatants, BCME (crystal matrix extract from blacks) and WCME (crystal matrix 
extract from whites), were dialysed in distilled water for 24 hours at 4°C, then lyophilised 
and resuspended in distilled water (100 III of water per 10.0 mg of extract). BCME and 
WCME were then analysed by 10 % SDS-PAGE and Western blotting. 
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2.2.2 Isolation of Albumin from Concentrated Urine Using a CNBr - anti-HA 
Sepharose Column 
Coupling of anti-HA to CNBr activated sepharose 
2.86 g CNBr sepharose beads (Sigma) were activated by suspension in 600 ml ice-cold 1 
mM HC}, washed for 15 min and filtered using a sintered glass funnel. 1.00 ml of a 21.9 
mg/ml anti-HA (Sigma) solution was added to 25.0 ml of 100 mM NaHC03 in 500 mM 
NaCl, pH 8.3. The beads were transferred into the solution containing the antibody and 
coupled overnight at 4 0c. Following filtration, the beads were resuspended in 50.0 ml of 
1.00 M ethanolamine, pH 8, and rotated for 2 hours to block free binding sites. Excess 
adsorbed protein was washed away using 250 ml 100 mM NaHC03 in 500 mM NaCl, pH 
8.30, followed by 500 ml 100 mM sodium acetate buffer in 500 mM NaCl, pH 4.00, and 
followed by 250 ml 100 mM NaHC03 in 500 mM NaCl, pH 8.30. The beads were then 
transferred to a 10.0 ml column. The column's binding efficiency was tested with 20.0 ml 
0.1 mg/ml solution of commercial HSA. 
Purification of albumin from concentrated urine 
Samples from black and white subjects, previously equilibrated in PBS (section 2.2.1), 
were centrifuged at 3939 g for 15 min, and then loaded onto the column at a flow rate of 
00400 ml/min. The column was subsequently washed thoroughly with PBS. A more 
stringent wash followed using 1 M NaCl in PBS. Albumin was eluted with 100 mM 
glycine, pH 2.80 and neutralised by the addition of a few drops of 1.00 M Tris, pH 9.50. 
The fractions containing the protein were pooled and dialysed extensively against distilled 
water at 4°C. Protein concentration was measured using the Bradford protein assay 
(Bradford, 1976). 
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2.2.3 Albumin Isolation from Crystal Matrix Extract Using a Protein G - Anti-HA 
Sepllarose Column 
Coupling and cross-linking of anti-HA to Protein-G Sep/tarose 
0.4 g protein-G sepharose was washed three times in 10.0 ml PBS, pH 7.50, then 
transferred to 10.0 ml of a 7.65 mg/ml solution of anti-HA (Sigma) in PBS and rotated 
overnight at 4 0c. The mixture was centrifuged and the beads washed three times in 10.0 
ml PBS. Cross-linking of bound antibody to protein-G involved resuspending the beads in 
3.00 M NaCL 50.0 mM borate buffer, pH 9.00 and incubating for one hour in 20.0 mM 
dimethylpimelimidate (DMP). This was followed by washing with 200 mM ethanolamine, 
pH 8.00, resuspension in ethanolamine and incubation at room temperature for 2 hours. 
Finally, the mixture was centrifuged for one minute, washed with PBS and transferred into 
a 2 ml column. 
Purification of albumin from crystal matrix extract 
Crystal matrix extract from each race group, resuspended in distilled water, was passed 
through the column at a flow rate of 0.4 ml/min, and then washed overnight with PBS to 
ensure the removal of any unbound material. As before (paragraph 2.2.2), albumin 
fractions were eluted with 100 mM glycine, pH 2.80 and neutralised by the addition of a 
few drops of 1.00 M Tris, pH 9.50. Fractions were pooled and dialysed overnight against 
distilled water at 4°C. The Bradford assay was used to determine the protein 
concentration in the dialysate (Bradford, 1976). 
2.2.4 Bradford Protein Concentration Determination 
The Bradford method was followed to measure protein concentration (Bradford, 1976). 
Standard solutions of bovine serum albumin (BSA) were prepared as specified by the 
manufacturers (BioRad Laboratories, Hercules, Calif. USA). OD595 nm readings were taken 
against a reagent blank and used to plot a protein standard curve from which protein 
concentrations were determined. 
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2.2.5 SDS Polyacrylamide Gel Electrophoresis 
Proteins were analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). Proteins were separated on a 10 % Polyacrylamide mini-slab gel using the 
BioRad Mini-Protean II apparatus (BioRad Laboratories, Hercules, Calif. USA). The 
samples as well as a low molecular weight marker (LMM) were dissolved in sample 
application buffer and boiled for five minutes. The gel was run at 25.0 rnA constant current 
for one hour. Protein bands were stained with Coomassie brilliant blue, or transferred 
onto nitrocellulose membrane (Amersham Life Science, Germany) for immunological 
identification by Western blotting. (Please refer to appendix for SDS-PAGE solutions). 
2.2.6 Western Blotting 
Proteins were immunodetected by Western blotting. Following electrophoresis, the 
proteins were transferred onto a nitrocellulose membrane at 100 V for one hour at room 
temperature using a transfer buffer consisting of 150 mM glycine, 20 % methanol and 20.0 
mM Tris, pH 8.30. 
The nitrocellulose membrane was incubated for an hour in blocking buffer containing 20.0 
mM NaCl, 5 % skim milk, 0.1 % Tween-20 and 50.0 mM Tris, pH 7.40. The membrane 
was subsequently immersed in anti-HA (Sigma), the primary antibody, at a 1:1000 dilution 
in blocking buffer for 90 min and then washed six times, each wash being a minute long, 
with blocking buffer before incubation in the secondary antibody - Peroxidase-labelled 
affinity purified antibody (KPL Europe, Guildford, UK) - at a dilution of 1 :2000 in 
blocking buffer for 60 min, then washed six times again in blocking buffer. 
The developer contained 24.0 mg 4-chloro-l-naphthol in 8.00 ml ice cold methanol, 40.0 
ml Tris buffered saline and 20 j.l/ H202. The bands were allowed to develop in darkness 
until the desired exposure had been reached. Then the developer was poured off and the 
membrane rinsed in distilled water. 
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2.3 Results 
2.3.1 Optimisation of Demineralisation 
Protein extracts from calcium oxalate crystals that were demineralised in 10.0 ml and 100 
ml of EDT A were analysed by 10 % SDS-PAGE and Western-blotting (Fig 6). 
2 3 2 3 
J20kDa -7 
80kDa -7 
66kDa -7 
66kDa -7 
Fig 6.1 Fig 6.2 
Fig 6: 10 % SDS-PAGE (Fig 6.1) and Western blot (Fig 6.2) of proteins obtained from 
demineralised calcium oxalate crystals induced in urine from white subjects (WCME). Lane 
I is commercial HSA , lane 2 and 3 correspond to WCME that was demineralised in 10.0 ml 
and 100 ml EDTA respectively. 
Crystals demineralised in 10.0 ml EDT A gave a prominent band at 66 kDa (Fig 6.1, lane 
2), which the Western blot confirmed was albumin (Fig 6.2, lane 2). Demineralised 
crystals in 100 ml EDT A, gave prominent bands at 80 and 100 kDa and only a minor band 
at 66 kDa. The band at 80 kDa is likely Tarnm-Horsfall mucoprotein (THM) (Ryall, 
1997). Thus the optimum volume for demineralization was found to be 10ml. Earlier 
work by Atmani and co-workers (2002) has demonstrated that different proteins can be 
associated with newly formed crystals in urine and that these proteins do not all bind to the 
crystals in the same way. Albumin for example is an intermolecular protein, unlike UPTFI 
which is included in crystals, as such it requires only small volumes of EDT A for 
demineralisation. 
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2.3.2 lmmunoafftnity Chromatography Using CNBr-Activated Sepharose 
Anti-HA coupled to CNBr-activated sepharose beads was used to purify urinary albumin. 
Of the 21.9 mg anti-HA present in the coupling solution, 2.81 mg was present in the filtrate 
after coupJing. Thus, 87.2 % of anti-HSA had successfully been coupled to the CNBr-
activated sepharose beads. 
To test the column's binding efficiency, 20 ml 0.1 mg/ml solution of commercial HSA was 
applied to the column. Fig 7 shows the elution profile that was obtained. 
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Fig 7: Elution profile lor 0.1 mglml HSA on the CNBr-activated sepharose column as determined 
by UV absorbance at 280 nm. 2.00 mg HSA in 20.0 ml PBS (A) was loaded onto the column at a 
flow rate 010.4 mllmin, the column was then washed with /5.0 milM NaCl in PBS (B) , pH 7.50. 
The protein peak was eluted with /2.0 ml 100 mM glycine (C), pH 2.8. 
The sample application eluent contained 87.5 j.1g HSA (4.40 %; Fig 7 A), indicating that not 
all the albumin was binding to the column. The salt wash had 118 j.1g HSA (8.90 %; Fig 
7B) and the glycine wash contained 929 f.1g of HSA (46.5 %; Fig 7C). It is evident that the 
binding efficiency of the column is low. Even though 19.1 mg of anti-HA had successfully 
been bound to the CNBr matrix, the recovery of HSA was only 46.5 %. 
The elution profile (Fig 7) showed that albumin had successfully been bound by the 
antibody, since no peak was obtained during sample application. It seemed though that the 
salt solution used was strong enough to cause some of the bound albumin to leach off the 
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column. However, most of the protein remained bound until it was eluted with 100 mM 
glycine, pH 2.80. 
Albumin from 600 m! and 3.60 f of urine from black and white subjects, respectively, was 
purified using the CNBr - anti-HA affinity column. 0.368 mg and 1.17 mg of purified 
albumin was isolated from blacks and whites respectively. This translates to 0.613 mglf 
and 0.325 mglf of protein in urine from black and white subjects respectively. The purity 
of the isolated protein was analysed by 10 % SDS-PAGE and a single band at 66 kDa 
corresponding to albumin was observed in both BA and W A (Fig 8). 
HSA BA WA 
66kDa ~ 
Fig 8: 10 % SDS-PAG£ of the isolated proteins. Lane I: 2.00 pg HSA. lane 2: 4.00 pg EA. lane 
3: 4.00 pg WA. Coomassie brilliant blue was used to stain the protein bands. 
At this point, it was noted that the glycine peak was progressively decreasing with each 
applied sample. The column was therefore re-tested with 20 ml 0.1 mglml solution of 
HSA. Most of the protein was eluted during sample application and salt wash (profile not 
shown) suggesting that the anti-HA had leached off the column. Since the column was no 
longer binding albumin, a new column was prepared using protein-G sepharose, which 
binds to anti-HA in such a way that both binding sites on the antibody are exposed for 
maximum binding to albumin. 
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2.3.3 Immunoaffinity Chromatography Using Protein-G Sepharose 
The purity of anti-HSA was checked by 10 % SDS-PAGE before using it to prepare the 
protein-G sepharose column (Fig 9). 
1 2 3 4 
97 kDa 
66 kDa 
45 kDa 
30 kDa 
Fig 9: Non-reducing 10 % SDS-PAGE used to analyse the purity oj 
anti-HA . Lane I: 10.0 j1g HSA , lane 2: low molecular weight 
marker, lane 3: 10.0 pg anti-HA, lane 4: 8. 00 pg anti-HA. 
No mercaptoethanol was added to the samples containing the antibody. Immunoglobulins 
have 4 polypeptide chains. Two identical heavy chains (H) and 2 identical light chains (L). 
Hand L are linked by disulfide bonds. Mercaptoethanol is a reducing agent that breaks up 
disulphide bonds. Since no mercaptoethanol was added, the Hand L chains did not 
dissociate and a high molecular weight band was observed for the antibody as indicated in 
Fig 9. There is a very faint band at 66 kDa in the anti-HA lane, indicating the presence of 
trace amounts of albumin. However, as indicated in the next section, the column was 
thoroughly washed so this band was absent from future gels. The SDS gel showed that 
anti-HA had not degraded and was suitable for the preparation of the Protein-G sepharose 
column. 
Of the 76.5mg anti-HA present in the coupling solution, 21.7 mg was retained in the 
filtrate after coupling as determined using the Bio-Rad assay. 54.8 mg (71.5 %) of anti-
HSA had successfully been coupled to the protein-G sepharose beads. 
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Column Binding Experiments 
Protein-G sepharose was coupled to anti-HA as described previously. The column was 
equilibrated with 20.0 ml PBS. To test whether the cross-linking of the antibody to 
protein-G sepharose was successful, the column was washed with 10.0 ml 100 mM glycine 
at pH 2.80. The pH was readjusted to 7.40 with 20.0 ml PBS. This sequence (glycine 
wash at pH 2.80 followed by PBS wash at pH 7.40) was repeated once more. Since no 
peak was obtained from the second glycine wash it was concluded that the antibody was 
not leaching off the column (profile not shown). 
14.6 mg HSA was loaded onto the column, washed with PBS and then eluted with 100 mM 
glycine, pH 2.80 (profile not shown). The salt wash was excluded from this and all 
subsequent runs because experiments on the CNBr-activated column had shown significant 
quantities of HSA were eluted when this step was included. 
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Fig 10: Elution Profile for 0.234 mglml HSA on Protein-G Sepharose Column as 
determined by UV absorbance at 280 nm. 11.7 mg HSA in 50.0 ml PBS (AJ was 
applied to the column at a flow rale of 0.4 mllmin. II was subsequently washed 
with 20.0 ml (B) PBS and 10.0 mllOO mM glycine (CJ , pH 2.80. 
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Having primed the column with HSA, its binding efficiency was tested with 50.0 ml of a 
0.234 mg/ml solution of HSA, loaded at a flow rate of 0.4 mllmin. The elution profile 
confinned that the antibody was binding to albumin (Fig 10). 6.76 mg of protein was 
obtained in the sample application eluent. 0.031 mg and 3.99 mg HSA was recovered in 
the PBS wash and glycine eluent respectively. Of the 11.7 mg HSA that was applied to the 
column, about 4 mg was recovered (i.e. only 34 % bound to the column). 
10.0 flg of protein from each of the eluents in Fig 10 was loaded onto a 10 % 
polyacrylamide gel and stained with coomassie brilliant blue. Each sample had a 
prominent band at 66.0 kDa which corresponds to HSA (Fig II). 
2 3 4 
97 kDa 
66 kDa 
45 kDa 
30 kDa 
FigJl: 10 % SDS-PAGE was used to analyse 10.0 J1g of protein from peak A and C (in jig /I 
above) and their mobility compared to that of commercial HSA (that had not been loaded onto the 
column). Lane! : commercial HSA (no/from column), lane 2: low molecular weight marker, lane 3: 
peak A, lane 4: peak C. 
Having established the binding efficiency of the column 129 ml BCME (prepared from 
1.82 I urine from black subjects) and 247 ml WCME (prepared from 6.61 I urine from 
white subjects) was applied and HSA eluted as described above. After dialysis, 1.46 mg 
and 4.91 mg of albumin was recovered from BCME and WCME respectively. This 
translates to 0.800 mg/I and 0.740 mg/I of protein in urine from black and white subjects 
respectively. The protein yield was four-fold higher than the yield obtained using the 
CNBr column. Thus the protein-G column gave a better yield (table 1). 
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Table 1: Comparison of the amount of albumin isolated using two different matrices 
Concentration of Albumin (mg/I) 
Race Group CNBr - Anti-HA Protein-G - Anti-HA 
Black Subjects 0.613 0.802 
White Subjects 0.325 0.743 
The purity of albumin isolated from crystal matrix extracts of black and white subjects was 
confirmed by 10 % SDS-PAGE (Fig 12) and Western blotting (Fig 13). The gel confirmed 
that the molecular weight of BA and W A are similar to that of commercial HSA. Since all 
the lanes showed a single band, it was decided that the isolated protein had been 
sufficiently purified and could therefore be used for crystallisation experiments. 
LMM HSA WA WA BA BA 
97 kDa 
66 kDa 
45 kDa 
30 kDa 
Fie 12: 10 % SDS-PAGE of albumin from black (BA) and white (WA) subiects. 
Immunodetection of the isolated protein by Western blotting (Fig (3) confirmed that the 
isolated protein was indeed albumin. Both high molecular weight and low molecular 
weight bands were observed in the commercial HSA. Wiggins et al (1985) explained that 
the high molecular weight bands are likely to be albumin polymers while the low 
molecular weight bands are albumin fragments. These authors determined that proteolysis 
of the albumin molecule occurred at sites both inside and outside disulphide loops 
(Wiggins et ai , 1985). Their observation has been confirmed by Cerini et al (1999). This 
could explain the low molecular weight bands seen in BA and W A. 
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BA WA HSA M 
190 kDa 
120 kDa 
85 kDa 
60 kDa 
50 kDa 
40 kDa 
25kDa 
Fig 13: Western blot a/purified albumin from black (SA) and white (WA) subjects. 
2.4 Discussion 
This chapter focused on the isolation of un nary albumin by immunoaffinity 
chromatography. Two approaches were used. The first involved the preparation of 
concentrated urine samples, from which albumin was isolated on a CNBr-activated 
sepharose column. Even with extensive dialysis and centrifugation, the concentrated 
samples clogged the column and reduced its efficiency. Also, the binding capacity of the 
column was low. 19.1 mg of anti-HA had been coupled to the CNBr matrix, yet the 
column was binding just under 1.00 mg as shown in Fig 7. This is because the antibody 
binds to the matrix via free amine groups which are present both in the Fc region and in the 
substrate binding regions of the antibody. Thus, the orientation of the antibody coupled to 
the CNBr matrix is not optimal for albumin binding. In addition, with repeated use, the 
column bound progressively lower amounts of albumin, possibly because anti-HA may 
have leached off. To avoid these problems, a new method of sample preparation was 
required and a different matrix was used. 
One approach to establishing the association of proteins with crystals is to study them in 
calcium oxalate crystals freshly precipitated from healthy human urine since they will not 
contain proteins that are released secondarily due to tissue damage (Finlayson et aI., 1961; 
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Khan et aI., 1987; Morse et aI., 1988; Morse et al., 1989; Doyle et aI., 1991). Studies by 
Atmani et al. (2002) have demonstrated that albumin is a major constituent of the crystal 
matrix extract. In the present study, crystal matrix protein was extracted by demineralising 
crystals with EDT A solution. Analysis of the isolated protein by 10 % SDS-P AGE and 
Western blotting confirmed it to be albumin. The results obtained demonstrated that this 
was the better of the two approaches used because a higher yield was obtained. 
The protein-G sepharose column was used to isolate albumin from 129 m} and 217 ml 
crystal matrix extract from the urine of black and white subjects respectively. 1.820 I of 
urine was obtained from 2 black subjects and 7 white subjects collected 6.610 I of urine. 
Therefore, the concentration of albumin in urine is 0.802 mg/! in blacks and 0.743 mg/! in 
whites. Since only two black subjects were used, the calculated concentration of albumin 
in blacks is not representative, nor can any conclusions be drawn whether these levels are 
statistically different. Cerini and co-workers have reported that on average, albumin 
excretion in healthy subjects is about 2.40 mgl24hr (Cerini et al., 1999). 
Despite the problems encountered, albumin was successfully isolated from urine of black 
(BA) and white (WA) subjects and used for crystallisation experiments. 
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CHAPTER 3: CRYSTALLISATION EXPERIMENTS 
3.1 Introduction 
The inhibitory or promotory effects of urinary components or whole urine itself on CaOx 
crystallisation in vitro have been studied using different techniques (Baumann et aI., 1989; 
Hess et aI., 1996; Hess et aI., 2001). This chapter considers the potential role of urinary 
albumin in the inhibition or promotion of CaOx crystallisation. Crystallisation 
experiments which were undertaken and which are described are the determination of 
calcium oxalate metastable limits, crystallisation kinetics, Coulter Counter measurements 
of particle volume-size distribution, [14C]-oxalate crystal deposition rates, x-ray powder 
diffraction analysis, zeta-potential measurements and crystal sedimentation rates. A brief 
discussion of each of the techniques is presented in the following paragraphs. 
Calcium Oxalate Metastable Limit 
The physicochemical processes in urolithiasis have been described in chapter 1. As stated 
previously, urine is supersaturated with respect to CaOx; crystals fom1 by nucleation and 
thereafter increase in size by crystal growth and/or aggregation (Kavanagh et aI., 1993). 
For CaOx stone formation, it is of interest to know up to what supersaturation the 
metastable zone extends. One way of achieving this is by progressively increasing the 
oxalate ion concentration (added as NaOx) and measuring the optical density of the 
solution at 620nm (OD620 nm). The CaOx metastable limit corresponds to the lowest 
concentration of N aOx that causes nucleation of CaOx. This is observed as a sharp 
increase in OD620 nm (Hess et aI., 1996). 
Calcium Oxalate Crystallisation Kinetics 
Once the limit of metastability has been determined, supersaturation is increased in one 
step by the addition of oxalate at a concentration of 0.300 mM in excess of the metastable 
limit. The ensuing crystallisation kinetics is measured by monitoring the increase in OD620 
nm as a function of time. Inhibition or promotion of crystallisation in the presence of 
albumin (or any other inhibitor) can be estimated in this way (Kavanagh et aI., 1993). The 
increase in OD620 nm in the first few minutes is due mainly to nucleation. However, the 
data will always reflect the overall crystallisation process. As such, the results obtained 
from these experiments give a general reflection of the crystallisation potential of urine 
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samples. Measurements can be performed under stagnant or agitated conditions. In the 
latter case, extra contributions of crystal aggregation and secondary nucleation can take 
place and the results are system-dependent (Hess et aI., 1996). In addition to CaOx 
crystallisation, particle formation may occur i.e. proteinaceous material may corne out of 
solution and may agglomerate with crystals. Interpretation of data must take this 
possibility into account. 
Particle Volume Size Distribution 
Another way of following crystallisation kinetics is to determine changes in particle 
volume-size distributions (Ryall et aI., 1985; Ryall et aI., 1991; Hess et aI., 1996). The 
appearance of particles above 2.00 11m is monitored within a fixed time period by the 
Coulter Counter. The crystal growth rate can be determined from the slope of the linear 
portion of increase of particle volume with time, or from total particle volume after 90 
minutes. The mean particle sizes can also be determined from the distribution (Ryall et aI., 
1986). Since the Coulter Counter measures particles whose sizes fall within a specified 
range (2.00 25.4 11m), crystals whose sizes lie outside this range will not be counted 
(Hess et al., 1996). Additionally, loose crystals containing empty spaces are recorded as if 
they are solid, thereby giving erroneously high estimates of crystal volume deposition. 
This problem is compounded by the occlusion of macromolecules into crystals. The 
Coulter Counter cannot account for differences in particle density. Therefore, to determine 
the true extent of mineral deposition, crystallisation must be induced using radioactive 
[14C]-oxalate; the disappearance of the latter from the test solution is indicative of crystal 
formation rather than particle formation. 
Crystal Deposition Kinetics Using Labelled tiel-Oxalate 
Radioactive isotopes can be used to determine the rate of precipitation of calcium oxalate 
from human urine in the presence and absence of inhibitors (Gill et al., 1974; Grover et aI., 
1998; Aggarwal et aI., 2000). Because the Coulter Counter measures particles and not 
crystals, precipitated proteins could interfere with the data (Edyvane et aI., 1987). It is 
therefore necessary to determine the actual amount of calcium oxalate crystals formed 
using labelled [J4C]-oxalate. The decrease in [J4C]-oxalate concentration at different time 
intervals is taken as an index of the rate of calcium oxalate crystal growth in metastable 
urine (Gill et al., 1974; Aggarwal et aI., 2000). 
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X-Ray Powder Diffraction Analysis (XRD) 
Irradiating a crystalline substance with x-rays produces diffracted rays. The intensity and 
direction of the diffracted rays depend on the unique arrangement of atoms in the 
crystalline sample. The intensities and spacings of the lines are then compared with a set 
of standards. X-ray diffraction analysis is therefore a useful technique for detennining the 
composition and thus the purity of a crystalline sample (Sutor et aI., 1968). In the present 
study, x-ray diffraction analysis was used to confirm the purity of calcium oxalate 
monohydrate (COM) crystals which were prepared for zeta potential and sedimentation 
experiments and also to confinn the composition of calcium oxalate crystals induced in 
urine samples as part ofthe protocol to isolate albumin. 
lntercrystalline Forces and Zeta Potentials 
Hess et al. (1996) have presented a summary of the forces that are presumed to be the most 
important for calcium oxalate crystal aggregation (Fig 14). 
Aggregation 
• Van der Waals 
• Viscous binding: 
Sticky properties 
of foreign 
molecules 
• Solid Bridges 
- stabilisation 
Intercrystalline Forces 
==~> Disaggregation < 
• Electrostatic repulsion: 
zeta potential 
• Shear forces 
• Turbulence (stirring) in suspensions 
• Solvent currents in tubular fluids 
Fig 14: Various forces favouring aggregation or disaggregation of calcium 
oxalate crystals in aqueous solutions and in urine (Hess et ai., 1996). Details are 
provided in text. 
Attractive Van der Waals forces increase strongly when interparticle distances are small, 
thus favouring aggregation. Aggregation is also encouraged by viscous binding of foreign 
compounds, such as macromolecules, to crystal surfaces. The strength of viscous binding 
depends on the attached foreign molecule; it might be so strong that it overcomes the 
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disaggregating zeta potential. Once an aggregate has been fonned, it may be stabilised by 
solid bridges - crystalline material connecting two particles. A dual aggregating as well as 
disaggregating force is the shear force exerted by stirring in crystalline suspensions or by 
solvent currents in tubular fluids. Shear force can promote aggregation by increasing the 
chance of particle collision; but it can favour disaggregation by disrupting particles (Hess 
et aI., 1996). 
The charge on colloidal particles can anse from a number of different mechanisms, 
including dissociation of acidic or basic groups on the particle surface, or adsorption of a 
charged species from solution (Finlayson et a/., 1984). The particle charge is balanced by 
an equal but opposite charge carried by ions in the surrounding liquid. These counter ions 
tend to cluster around the particles in diffuse clouds. This arrangement of particle surface 
charge surrounded by a diffuse cloud of counter charge is called the electrical double layer 
(Fig 15). The electrical potential drops off exponentially with distance from the particle 
and reaches a unifonn value in the solvent outside the diffuse double layer. 
or. 
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~ 
. /Decayof potential In the 
,. diffuse double layer. 
Electrical 
Potential 
I 
I 
I 
I Distance ., OLJ __________________________ _ 
Fig 15: A schematic diagram of the electrical double layer 
(http://www.bic.com/ztheoryl /htm). 
The zeta potential is the voltage difference between a plane a short distance from the 
particle surface and the solvent beyond the double later (Finlayson et aI., 1984). Thus, the 
zeta potential is the electrical potential at the interface between a colloidal particle (solid 
phase) and its surrounding solution (continuous phase) (Boeve et aI., 1994). In the context 
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of kidney stone research, the zeta potential has been employed to study the stability of 
urinary colloidal systems and the mechanism of crystal aggregation. Zeta potentials have 
been measured for several inhibitors (Hess et al., 1989; Cao et aI., 1992; Boeve et aI., 
1994; Cao et aI., 1996). In such studies, an increase in the negative charge of the zeta 
potential has been interpreted as an increase in inhibition of aggregation (Scurr et aI., 
1986). 
Measurement of Aggregation by Crystal Sedimentation 
It is possible to measure COM crystal aggregation in the absence of COM crystal growth, 
based on the terminal sedimentation velocity of COM crystal aggregates produced by slow 
stirring of an equilibrated COM crystal slurry (Hess et aI., 1989). 
Fig 16 shows a typical time course of OD620 nrn of the COM crystal slurry. During slow 
stirring, left of arrow, OD620 nrn (y-axis) falls hyperbolically, to reach a plateau by 180 s. 
The fall in OD620 I1rn during the 180 s is due only to aggregation, since the equilibrium 
solution permits neither crystal growth nor dissolution. After stirring is stopped (arrow), 
OD620 nrn falls at a rate that becomes constant at time l' (x-axis), when OD620 nrn is OD'. 
The decrease in OD620 nm is due to particle settling, which is controlled by particle size. 
The x-intercept of the linear portion gives to, time by which OD620 11m would have reached 
zero, if particles settled at constant maximal rate. The slope of the linear portion of the 
curve, called the turbidity slope, or Ts is (0 OD')/(lo 1') (Hess et aI., 1989). In every 
sedimentation experiment, the slope (Ts) of the linear regression of OD620 11m versus time 
was calculated. 
Percent of crystal aggregation in the presence of inhibitors is calculated as (TslTsc) X 100, 
where Tsc is the turbidity slope of the control; inhibition data are presented as 100 % -
%Aggregation (Hess et aI., 1989). 
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Fig 16: Spectrophotometric determination of COM crystal aggregation in the absence oj 
COM Cfystal growth modified from Hess et al.. 1989. For details. see text. 
3.2 Methods 
3.2.1 Subjects and Urine Collections 
Single 24-hour urine samples were collected in 2.00 I plastic bottles from each of three 
male subjects in each race group. The subjects were aged 20-27 years and were recruited 
from students at the University of Cape Town. Individual samples were tested for blood 
and infection using urinalysis test strips (Combur 10 test strips; Boehringer Mannheim), 
then filtered with a pre-filter (Macherey-Nagel), followed by a 0.420 pm Millipore filter 
(Millipore Corporation, Bedford) in order to remove cellular debris. This does not affect 
the concentration of calcium and oxalate as inferred from previous studies (Robertson et 
ai., 1972; Baumann et aI., 2000). Urine samples were ultra-filtered using an Amicon 
hollow fibre bundle (H I P 10) with a nominal cut-off at 10 kDa relative molecular mass. 
This yielded ultrafiltered urine (UF) from black and white subjects. Prior to each 
crystallisation experiment, the metastable limit of the ultra filtered urine was determined. 
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3.2.2 Metastable Limit (MSL) 
0.200 M sodium oxalate (NaOx) stock solution was prepared by dissolving 2.68 g of the 
salt in 100 ml of water. From this stock solution, the following sodium oxalate standard 
solutions were prepared for metastable limit determination. 
Table 1: Preparation ofNaOx standard solutions 
Vial Cone. (molldm3) Stoek Solution (m) Distilled Water (m) 
1 0 0 10.0 
2 0.015 0.75 9.25 
3 0.030 1.50 8.50 
4 0.045 2.25 7.75 
5 0.060 3.00 7.00 
6 0.075 3.75 6.25 
7 0.090 4.50 5.50 
8 0.100 5.00 4.75 
9 0.130 6.50 3.25 
10 0.150 7.50 2.50 
11 0.165 8.25 1.75 
12 0.180 9.00 1.00 
13 0.195 9.75 0.25 
The metastable limit of each UF sample was determined as follows: 2.00ml UF was 
dispensed into each of fourteen 2ml ependorphs and incubated in an oven thermostated at 
37.0 °c for 10.0 min. Tube 1, the blank, contained no NaOx. Tubes 2-14 were dosed with 
20.0,u1 of progressively increasing concentrations ofNaOx (as shown in above table) at 2 
min intervals. OD620 nm (turbidity) was recorded using a spectrophotometer (Helios 
Gamma and Delta, Cambridge) 30 min after each dose (n 2). The metastable limit was 
determined from a plot of OD620 nm vs. time, which showed the concentration of NaOx that 
led to spontaneous nucleation of calcium oxalate crystals a sharp increase in OD620 nm is 
observed (Fig 17). 
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Fig 17: A typical graph showing the metastable limit as a sharp rise in OD620 nm. 
3.2.3 Particle Formation Kinetics 
One 24-hour urine sample was collected from each of three subjects in each race group. 
After testing for blood and infection, the samples were filtered and ultrafiltered as 
described previously. For each ultrafiltrate (UF), the metastable limit was determined 
using the above protocol, and then particle formation kinetics were determined as follows: 
2.00 ml UF was dispensed into four 2.00 ml ependorph tubes. With the exception of the 
control, 2.00 ,ug of each of the commercial human serum albumin (HSA), the albumin 
isolated from urine of black subjects (BA) and the albumin isolated from urine of white 
subjects (W A) were added to the remaining three tubes respectively. The tubes were 
incubated in an oven thermostated at 37.0 DC for 10 min, and then dosed with 20.0 ,ul of 
NaOx at a concentration of 0.030 mol/dm3 in excess of the metastable limit. This was 
taken as time t = o. Thereafter OD620 nm was measured at 10 min intervals for 90 min (n = 
3). The rate of particle formation (kinetics) was determined from a graph of OD620 nm vs. 
time. The experiment was carried out in triplicate for each individual sample. Fig 18 is a 
representation of a typical kinetics graph. 
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Fig 18: Graph of OD620 nm vs. time. The rate of particle formation can be determined by 
calculating the gradient of the linear portion of the graph. 
3.2.4 Particle Volume - Size Distribution 
90.0 
A 24-hour urine sample was collected from each of two subjects in each race group. After 
testing for blood and infection, the samples were filtered and ultrafiltered as described 
previously. 10.0 ml UF urine containing 1.00 Jig/ml each of the HSA, the W A and the BA, 
as well as a control, from two individuals per race group were incubated in an oven 
thermostated at 37.0 °c for 10 min. After dosing with 100 Jil NaOx at 0.030 mol/dm3 in 
excess of the previously determined metastable limit, Coulter Counter measurements for 
particle volume-size and particle number-size distributions were taken at t = 90 min. 
3.2.5 Measurement oft4C/-oxalate Crystal Deposition Kinetics 
A 24-hour urine sample was collected from each of three subjects in each race group. 
After testing for blood and infection, the samples were pooled and then filtered and 
ultrafiltered as described previously. 15.0 ml of BUF and WUF was added to four 100 ml 
glass flasks labelled CTRL, HSA, W A, and BA which contained 15.0 I1g (1.00 Jig/ml) of 
the respective protein. The flasks were incubated in a shaking water bath set at 37.0 °c for 
10 - 15 min. 7.50 III of 14C was added, followed by 150 III of NaOx at a concentration of 
0.030 mol/dm3 in excess of the metastable limit. This was taken as time t = O. 2.50 ml of 
ultrafiltrate was taken from each flask and passed through a filter attached to a syringe into 
0.250 ml concentrated HCI to quench the reaction. 1.00 ml of this mixture was transferred 
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into 10.0 ml scintillation fluid (n = 2). The process was repeated at 30, 60, 90, 120 min 
time intervals. A scintillation counter (Malvern instruments; UK) was used to monitor the 
amount of [14C]-oxalate remaining in solution at the various time intervals. Subtraction of 
this value from that recorded at time t = 0 gave the quantity of precipitated CaOx. Percent 
precipitated oxalate vs. time was plotted to determine the effect of the different proteins on 
calcium oxalate crystal deposition. Since the scintillation counter measures the 
radioactivity due to un-precipitated [14C]-oxalate, there is no significant error caused by the 
sticking of [14C]-oxalate to the wall of the vials and the crystal-mass on the filter. 
3.2.6 Preparation of Calcium Oxalate crystals 
Preparation of Pure Calcium Oxalate Monohydrate Crystals for Zeta Potential 
Measurements and Sedimentation Experimentj' 
COM crystals were prepared as described by Pak et al. (1975). Using two line feeds, 500 
ml of 10.0 mM CaCh and 500 ml of 10.0 mM NaOx were mixed simultaneously at room 
temperature at a rate of 1.00 mllmin using a peristaltic pump. The mixture was then stirred 
for a week at 6.00 0c. Crystals were then filtered through a 0.220 pm filter paper, washed 
with 2.00 ml of methanol and dried in an oven at 95.0 °c for an hour. X-ray powder 
diffraction analysis was used to confirm the presence of COM. 
Preparation of Calcium Oxalate Crystals in whole Urine for Protein Isolation 
24-hour urine specimens were collected from 2 healthy black and 2 healthy white male 
subjects and were then pooled after confirming the absence of blood and infection. An 
adapted method of that described by Atmani et al. (2002) was used for the induction of 
calcium oxalate crystallisation in whole urine. Pooled urines from the race groups were 
warmed to 37.0 °c in a shaking water-bath. CaOx crystallisation was induced by drop-
wise addition of 15.0 mIll of 100 mM sodium oxalate solution at pH 5.90 - 6.50. After 1 
hour, the same amount of sodium oxalate was added to the mixture. An hour later, the 
crystals were harvested by centrifugation at 8000 g using a lR-20 rotor (Beckman 
Instruments, Fullerton, Calif. USA) for 30 min at room temperature. The calcium oxalate 
crystals grown in whole urine from black and white subjects were then analysed by x-ray 
powder diffraction. 
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3.2.7 Zeta Potential Measurements 
Four vials containing 11.0 m] 0.300 mg/mi COM crystal slurries were prepared in 10.0 
mM sodium acetate buffer, pH 5.70 and were equilibrated overnight with constant stirring 
(1100 rpm) at 25.0 °c (Hess et al., 1989). Besides the control, which had no protein, 1.00 
Jig/ml each of the HSA, the W A and the BA was added to each of three vials respectively 
and stirring continued for 2 hours at 37.0 °c and 1100 rpm. The zeta potential of the COM 
slurry in each vial was measured in duplicate using a Zetasizer 4 (Malvern instruments; 
UK). Five different runs were carried out and a mean obtained for the effect of each 
protein on the zeta potential of the COM crystal slurry. 
3.2.8 Rate of Sedimentation 
The spectrophotometric assay method developed by Hess et al. (1989) was used for the 
measurement of COM crystal aggregation in the absence (control), and presence of 
albumin (HSA, BA and WA). COM crystals prepared as described in section 3.2.6 were 
dissolved in 10.0 mM Tris-HCl buffer, containing 90.0 mM NaCI, pH 7.50 to yield COM 
slurries. The concentration of the COM crystal slurries was 0.800 mg/mt. Four vial 
containing 7.00 ml 0.800 mg/ml crystal slurries were equilibrated overnight in a water 
jacket set at 37.0 °c, with continuous stirring at 1100 rpm. After equilibration, 1.00 Jig/ml 
each of the HSA, the W A and the BA was added to three vials respectively and stirring 
continued for 2 hours at 37.0 °c and 1100 rpm. 
A 2.00 ml aliquot of slurry was then transferred into a 10.0 mm cuvette in a cell holder 
thermostated at 37.0 °c, with continuous stirring at 1100 rpm. OD620 nm was measured at 
5.00 sec intervals for 5 min, 10.0 sec intervals for 10 min or until OD620 nm was 
unchanging. At this point, the stirrer was turned off: and OD620 nm was recorded until there 
was no more change in absorbance due to particle settling (Hess et al; 1989). Three sets of 
OD620 nm were obtained per run for each vial - the control (CTRL), HSA, BA and W A. In 
each sedimentation experiment, the slope (Ts) of the linear regression of OD620nm versus 
time was calculated. Percent of crystal aggregation in the presence of protein was 
calculated as (TsiTsc) X 100, where Tsc is the turbidity slope of the control. Percentage 
inhibition is therefore represented as 100 % - %Aggregation (Hess et al., 1989). A total of 
five runs were carried out on five different days and an average obtained. 
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3.3 Results 
3.3.1 Metastable Limit (MSL) 
It is well-known that urine is supersaturated with respect to CaOx (Nordin et ai., 1993; 
Hess and Kok; 1996; Baumann et a1. , 1997). Determining the metastable limit of a urine 
sample provides the investigator with information on the tendency for crystals to form, and 
is also an indication of the urine sample's ability to inhibit crystal nucleation. The 
metastable limit is of great practical significance for excretion of poorly soluble salts as it 
represents the boundary of supersaturation that might be sustained without formation of 
crystals or stones (Kavanagh, 2000). The mean plots of OD62onm vs. concentration of 
NaOx for the determination of metastable limits in the urines of black and white subjects 
are given in Fig 19 (a) and (b) respectively. 
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Fig 19: Mean plots for the determination of metastable limit of urine samples from 8 
black subjects (a) and from 9 white subjects (b) . 
These plots show that CaOx crystal formation in the urine of blacks is more difficult to 
initiate than in the urine of whites. This supports the general observation that kidney stone 
disease occurs rarely in the black race group. Urine composition and physicochemical 
data for the various urines are given in appendix II, pages 106-7. 
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3.3.2 Particle Formation Kinetics 
As mentioned previously, supersaturation IS the driving force of crystallisation. In a 
supersaturated solution, the resultant kinetics of crystal formation consists of one or more 
of the following mechanisms - nucleation, crystal growth, crystal aggregation and phase 
transformations (Hess and Kok; 1996). The rates at which these processes occur will 
determine the characteristics of the inorganic material formed, such as crystal phase, 
particle shape, particle size and number of particles. These rates in tum are dictated by the 
solution chemistry (Hess and Kok; 1996). 
The effect of 1.00 ,Ltg/ml each of HSA, BA and W A on calcium oxalate crystallisation 
kinetics in BUF, relative to the control is shown in Figs 20 and 21. 
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Fig 20: Graph of OD1520 nm vs. time from which the rate of particle formation in BUF in the 
presence and absence of albumin was determined. 
The rate of particle formation in BUF as determined from the gradients of the above curves 
follows the trend CTRL = BA < W A = HSA. 
After 90 min incubation, the total amount of crystal formation, measured as 00620 nm is 
shown in Fig 21 . 
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Fig 21: A comparison of the total amount of particles present in BUF containing the different 
proteins after incubation with NaOx for 90 min. 
The trend observed after 90 min is CTRL<BA<WA=HSA. These results indicate that the 
proteins promote CaOx crystal formation in BUF. W A and HSA have a greater effect in 
BUF than BA. 
Results obtained for the effect of 1.00 ,ug/ml each of HSA, BA and W A on calcium oxalate 
crystallisation kinetics in WUF are shown in Figs 22 and 23. 
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Fig 22: Graph of OD620 tim vs. time from which the rate of particle formation in WUF in 
the presence and absence of albumin was determined. 
The rate of particle formation in WUF as determined from the gradients of the above 
curves follows the trend BA = HSA < W A < CTRL. 
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Fig 23: A comparison of the total amount of particles present in WUF containing the 
different proteins after incubation in NaOxfor 90.0min 
The trend observed after 90 min is BA=HSA<W A<CTRL. These results indicate that the 
protein inhibits CaOx crystal formation in WUF. 
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3.3.3 Particle Volume -Size Distribution 
The Coulter Counter was used to monitor formation of particles above 2.00 .urn at time t = 
90 min after dosing with NaOx solutions. The particle volume-size distribution and 
particle number-size distribution are given in Fig 24. In general, a decrease in total particle 
volume can arise from three possible events - fewer particles, smaller particles or less 
aggregation (Hess et aI., 1995). Particle volume-size and particle number-size distributions 
are given in Fig 24 (a) and Fig 24 (b) respectively. 
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Fig 24: The above distribution curves are for particle volume - size (a) and particle 
number - size (b) that was obtained in urine from black subjects at time t = 90.0min 
It is observed that in BUF, particle volumes and particle numbers are relatively small. The 
volume-size distribution, Fig 24 (a), shows 3 peaks at approximately 7.um, 14.um and 21 
.urn. However, the number-size distribution, Fig 24 (b), shows only one ill defined peak < 
5 .urn. Because of the low particle numbers, the volume distribution may be strongly 
influenced by single atypical crystals. As such, the volume-size distribution will not be 
considered further. The number-size distribution shows the trend, CTRL<BA=W A=HSA. 
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Particle volume-size and particle number-size distributions in WUF are given in Fig 25 (a) 
and Fig 25 (b) respectively. It is noted that particle numbers are an order of magnitude 
greater than in BUF. Volume-size (Fig 25a) and number-size (Fig 25b) trends tend to 
agree, albeit that the peaks are not well defined. 
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Fig 25: Particle volume - size (a) and particle number - size (b) distribution curves 
obtained in urine from white subjects at time t = 90 min 
The additional peaks for HSA and W A (at approximately 13 ,urn) in the volume-size 
distribution and their absence in the number-size distributions again suggest the possible 
presence of single atypical crystals. As in BUF, these peaks will not be considered further. 
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3.3.4 Crystal Deposition Kinetics Using Labelled /4Cj-Oxalate 
The effect of albumin on the deposition of labelled [14C]-oxalate in BUF is shown in Fig 
26. As explained earlier, the Coulter Counter has an inability to distinguish crystals from 
particles which may result in precipitated proteins being incorrectly interpreted as crystals. 
A decrease in [ 14C]-oxalate concentration, monitored using a scintillation counter, at 
different time intervals provides a measure of the rate of CaOx crystal formation In 
metastable urine (Gill et aI., 1974; Aggarwal et aI., 2000). 
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Fig 26: The rate ofCaOx crystal deposition in pooled BUF in the presence and absence of 
albumin is given by the gradient of the linear section of the curve,from t = 0 to t = 30 min 
The CaOx deposition rates in BUF as determined by the gradients of the curves during the 
first 30 min follows the trend WA<BA=HSA<CTRL. Thus, WA, BA and HSA inhibit 
CaOx deposition (Fig 26). 
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C HAPTER 3 
Albumin was found to inhibit CaOx deposition in WUF as well (Fig 27). The trend for the 
deposition rate was BA < WA < HSA = CTRL. 
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Fig 27: The rate ofCaOx crystal deposition in pooled WUF in the presence and absence of 
albumin is given by the gradient of the linear section of the curve, from t = () to t = 3{) min 
69 
-+-CTRl 
__ HSA 
__ WA 
-.-SA 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 3 
3.3.5 X-Ray Powder Diffraction Spectra for CaOx Crystals 
Fig 28 below indicates the relative intensity and interplanar spacings (A) of calcium 
oxalate crystals prepared for (a) zeta potential and sedimentation measurements and for 
protein isolation from the urine of (b) black and (c) white subjects. 
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Fig 28: X-ray Powder diffraction spectra for calcium oxalate cly stals. (a) Crystals prepared 
for zeta potential and sedimentation measurements using the method of Pak et at. (1975). For 
(b) and (c), crystals were precipitated from urine of black and white subjects respectively 
using the method of Almani el at. (2002). 
Comparison of the d-spacing (figures in bold) with standard tables published by Sutor et al 
(1968) indicates that Fig 28 (a) is pure COM. The spectrum obtained for Fig 30 (b) is 
characteristic of calcium oxalate dihydrate (COD). Fig 28 (c) is difficult to interpret due to 
noise interference. However, the peak at 2.85 A is characteristic of COD and that at 3.02 
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A is close to the COM characteristic peak of 2.97 A. The peak at 3.73 A is close to 
characteristic peaks of both COM and COD. Thus it appears that urine from black subjects 
produce mainly COD, while urine from white subjects produce a mixture of COM and 
COD when challenged with NaOx. 
3.3.6 Zeta Potential Measurements 
Fig 29 shows histograms for the mean zeta potentials of crystal slurries in the presence and 
absence of 1.00 ,ug/ml each of the HSA, the W A and the BA. 
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Fig 29: Mean zeta potentials of crystal slurries in the absence and presence of albumin. 
The negative charge (zeta potential) of COM crystal slurries increased in the presence of 
all three proteins. Values followed the sequence BA (-19.3 mY), WA (- 16.9 mY), HSA (-
14.2 mY) and COM control crystals (- 13.0 mY). BA carries a more negative charge than 
W A and will therefore exert stronger repulsive forces and is likely be a superior inhibitor 
of crystal aggregation. 
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3.3.7 Rate of Sedimentation 
The spectrophotometric assay used for the measurement of aggregation by crystal 
sedimentation yielded the results shown in Fig 30. The crystal slurries contained 1.00 
,ug/ml each of the HSA, the BA and the A. 
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Fig 30: The percentage inhibition a/COM crystal aggregation by HSA, BA and WA. 
The percentage inhibition of COM crystal aggregation by HSA and W A was not 
significantly different (31.3 % and 35.1 % respectively). However, inhibition of COM 
crystal aggregation by BA was significantly higher (50.6 %). 
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3.4 Discussion 
The main reason why stone disease does not occur in all persons is that nonnal urine 
retards and inhibits crystallisation (Pak et aI., 1976; Coe et aI., 1991). To define the role 
of inhibitors in the formation of crystals and stones, it is customary to investigate 
crystallisation in vitro in the presence and absence of individual macromolecules, using 
either aqueous inorganic solutions, or urine itself (Ryall et aI., 1995; Asplin et aI., 1997; 
Maslamani et aI., 2000). In the current study, albumin from black and white subjects was 
investigated for its effect on CaOx crystallisation in inorganic media as well as in 
ultrafiltered urine from both race groups. 
Previous work on albumin has shown that it has no effect on the metastable limit (Edyvane 
et aI., 1987). As such, this study did not investigate the effect of albumin on this urinary 
parameter but simply compared the difference in the metastable limits of ultrafiltered urine 
samples obtained from black (BUF) and white (WUF) subjects without the addition of 
albumin. Fig 19 shows that the limit of metastability was 0.100 mol/dm3 and 0.045 
mol/dm3 for BUF and WUF respectively. These results together with the lower RScaox 
values in blacks compared to whites (appendix II, pages 106-7) suggest that urine from 
black subjects can tolerate higher levels of supersaturation without the fonnation of CaOx 
crystals, compared to urine from white subjects and as such, is in agreement with the 
significantly lower incidence of urolithiasis in this race group. The obvious question 
which arises is "does urine from black subjects contain inhibitors of CaOx crystallisation 
which are more potent than those which occur in urine of white subjects?" 
Before drawing conclusions regarding the inhibitory or promotory effects of albumin, it is 
essential that the data acquired by spectrophotometry, Coulter Counter and radioactive 
[14C]-oxalate be clearly understood and interpreted. 
Both spectrophotometry and Coulter Counter techniques suffer from the same limitation 
regarding their inability to distinguish between a "particle" and a "crystal" of calcium 
oxalate. Thus, an increase in optical density (in the case of spectrophotometry) or an 
increase in the number of particles (in the case of Coulter Counter) cannot be confidently 
attributed to the fonnation of only CaOx crystals. Other particulate matter (such as 
proteins) could be co-precipitating independently of the crystals or could be adsorbed onto 
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the crystal surfaces. The only way to measure CaOx crystal formation per se is to use a 
[14C]-oxalate deposition assay in which the rate of disappearance of the latter from the test 
solution provides a direct and quantitative measure of CaOx crystallisation kinetics. Thus, 
the data acquired by the three techniques spectrophotometry, Coulter Counter, [14C]_ 
oxalate deposition - must be considered in concert. 
In BUF, the C4C]-oxalate deposition rates followed the trend WA<BA<control, indicating 
that W A is a stronger inhibitor than BA. However, the results for spectrophotometry and 
for Coulter Counter (particle number) both show the trend to be CTRL ::s BA ::s WA, 
thereby indicating a significant amount of independent protein co-precipitation. (Protein 
adsorption onto CaOx crystal surfaces is probably also occurring but cannot be positively 
identified by these of data). 
In WUF, the formation rates for all the techniques fit a general trend BA < W A ::s CTRL. 
Thus, it can be concluded that in WUF, albumin from both race groups inhibits the rate of 
formation of CaOx crystals and that BA is more efficacious in this regard. In addition, it 
appears that co-precipitation of protein, if it occurs at all, is not an independent process i.e. 
it is probably being adsorbed directly onto CaOx crystal surfaces and as such, does not 
significantly increase the optical density or the number of particles. 
It is interesting to consider the above results in the light of previous studies. Reports of the 
effect of albumin on crystal growth in literature are contradictory. In some studies, its 
effect has been described as modest or absent depending on experimental conditions 
(Edyvane et aI., 1987; Worcester et aI., 1988; Grover et aI., 1998; Chen et a1., 2001). 
In a dilute seeded crystallisation system, albumin was found to be a weak inhibitor of 
crystal growth (Edyvane et aI., 1987; Chen et a1., 2001). On the other hand, Worcester et 
a1. (1988) reported that albumin has a strong affinity for COM crystals, yet did not inhibit 
crystal growth even at concentrations as high as 3 x 10-6 M. They therefore proposed that 
either almost all of the adsorption occurred at non-growth sites or the protein adsorbed to 
gro\\-1h sites but did not prevent growth. Similar results were obtained by Grover and 
associates (1998) who found that crystal growth, as measured by [14C]-oxalate 
disappearance was unaffected by albumin. In all of the above studies (Edyvane et aI., 
1987; Worcester et aI., 1988; Grover et aI., 1998; Chen et aI., 2001) commercial HSA and 
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not urinary albumin (as in the present study) was used. Also, the assay system used in the 
present study was different to that used by Edyvane et a1. (1987), Worcester et a1. (1988) 
and Chen et a1. (2001) but similar to that used by Grover et a1. (1998). However, in the 
latter study, the researchers carried out their investigations in inorganic medium and not in 
real urine as was the case in the present study. Thus, the fundamental difference between 
the protocols in previous studies and the present one could account for the different results. 
The current study has a significant advantage over the above mentioned ones because 
urinary albumin was used in real urine in order to determine its role in the inhibition of 
crystal growth. This is preferable to inorganic solutions because it more closely represents 
the environment in which stones are formed. It is clear from Figs 26 and 27 that albumin 
from both race groups inhibits CaOx crystal deposition. Also, their roles in urine from the 
different race groups are reversed. BA is a more potent inhibitor of CaOx crystal gro\\1h 
in WUF, while in BUF, WA displays a greater inhibitory effect than BA. Therefore, the 
nature of urine composition appears to affect albumin's performance. Perhaps the nature 
of urine influences the degree of aggregation of albumin. 
Other studies have revealed that in the presence of albumin, crystals which formed were 
smaller and more numerous than those in control solutions (Edyvane et a1., 1987; Ryall et 
aI., 1991; Hess et aI., 1995; Grover et ai., 1998; Cerini et aI., 1999). This apparent 
promotory effect of albumin on CaOx precipitation has been ascribed to the protein's 
ability to act as a microsubstrate for the deposition of calcium and oxalate ions and thereby 
induce heterogeneous nucleation of CaOx crystals (Ryall et al., 1987). Initiation of crystal 
nucleation would require that the protein provide an adequate template for the positioning 
of the ions that would form the first crystal lattice. Cerini et a1. (1999) proposed that the 
Ca2+ ions would bind preferentially to carbonyl or carboxyl groups on the protein. Then, 
because CaOx crystals present faces composed of alternate layers of calcium and oxalate 
ions, by diffusion and adsorption of calcium over the protein surface, albumin could 
stabilize calcium interactions by ionotropic effect and initiate crystal nuc1eation by ion 
pairing, allowing binding to oxalate ions (Cerini et a1., 1999). The formation of smaller 
crystals in greater numbers, as described above, was not observed in the present study, 
possibly because real urine was used in the latter. Albumin, irrespective of its origin, has 
been shown in the present study to be an inhibitor of CaOx crystallisation. However, the 
origin of the urine in which the albumin was tested, had an effect on the protein's 
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behaviour. In BUF, proteins from both race groups formed fewer crystals and their total 
volume was less than those crystals which formed in WUF. This observation demonstrates 
a synergistic relationship between protein inhibitory performance and urine environment. 
Similar results have been obtained for urinary proteins such as UPTFI (Durrbaum et aI., 
2001; Webber et al., 2003) and THM (Craig et aI., 2001). 
Crystal aggregation is considered to be more important for stone formation than crystal 
nucleation and gro\\th (Tiselius et al., 1995; Hess et al., 1996). The reason for this is that 
calcium oxalate gro\\1h is too slow to produce clinically significant particles within the 
transit time of urine in the urinary tract, whereas aggregation occurs within seconds and is 
thus more dangerous for the formation of large crystalline particles in renal tubules 
(Tiselius et aI., 1995; Hess et aI., 1996). Inhibition of crystal aggregation is related to 
changes in surface charge that occur when a macromolecule, like albumin, binds to 
crystals. The surface charge or zeta potential becomes more negative. This increases the 
electrostatic repulsive forces between crystals. 
In the present study, the negative charge (zeta potential) of the COM crystal slurries 
increased in the presence of all three proteins relative to the control i.e. the charge became 
more negative (Fig 31). Values followed the sequence BA (-19.3 mY) > WA (-16.9 mY) > 
HSA (-14.2 mY) > COM control crystals (-13.0 mY). These zeta potential values 
demonstrate that in the presence ofBA, COM crystals carry a more negative charge than in 
the presence of W A. As such, BA will exert stronger repulsive forces and is likely to be a 
superior inhibitor of crystal aggregation. 
The effect of albumin on CaOx aggregation was also investigated by measuring the 
terminal sedimentation velocity of COM crystal aggregates produced by slow stirring of an 
equilibrated COM crystal suspension. The results (Fig 30) show that albumin (irrespective 
of its origin) is an inhibitor of COM crystal aggregation and that BA is superior to W A and 
HSA in this regard. Albumin's inhibition of aggregation agrees with literature where it has 
been reported to inhibit COM crystal aggregation detectably at a concentration of 0.01 pM 
(Hess et aI., 1989). This trend confirms the interpretation of the zeta potential data which 
suggested that BA is a more potent inhibitor of COM crystal aggregation than HSA and 
W A. Since aggregation is probably the most crucial mechanism in stone formation, BA's 
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ability to inhibit this process may be one of the factors responsible for the rare occurrence 
of urolithiasis in black South Africans. 
In the conditions under which the zeta potential measurements were performed (acetate 
buffer, pH 5.7), some free calcium would be bound to the acetate and the free calcium I 
free oxalate ratio will be <1. In the sedimentation rate experiments, a Tris-HCI buffer, pH 
7.5 was used. Here more free calcium ions would be available, the free calcium I free 
oxalate ratio will approach unity and possibly, albumin is more protonated. In order to 
account for the pH difference in the two procedures, further studies will aim at 
investigating the behaviour of BA, W A and HAS under different calcium concentrations 
and pH values. 
X-ray diffraction data obtained in the present study demonstrated that urine from healthy 
black and healthy white subjects contained COD crystals and a mixture of COM and COD 
crystals respectively. This was contrary to expectations since recent literature has reported 
that urine from black subjects produced predominantly COM when NaOx is added 
(Webber et aI., 2003). The observed results cannot be attributed solely to albumin since 
the crystals were induced in whole urine. With pure compounds, it has been found by 
several investigators (Furedi-Milhofer et aI., 1995; Wesson et aI., 1998; Sikiric et aI., 1999; 
Wesson et al., 2000) that an inhibitor can stimulate COD formation by completely 
blocking COM nucleation. The driving force of supersaturation has to go somewhere, 
COM is preferred but when the route to COM is blocked COD will form. In future studies, 
scanning electron microscopy can be used to support the x -ray diffraction data as well as to 
show whether specific crystal surfaces of COM are being affected by adsorption of 
albumin to the crystals. It will also be worthwhile to perform nucleation experiments in 
the presence of increasing concentrations of albumin. This will provide information on 
whether albumin stimulates or inhibits nucleation and in addition show if albumin has a 
preference for a specific crystal surface. Furthermore, it may show differences in action 
between BA, W A and HSA. A molecular basis for the observed inhibitory differences will 
also be explored by conducting biochemical analysis of the different proteins. 
The formation of COD over COM in the unne of healthy black subjects would be 
advantageous because the interaction of COM crystals with renal cells has been shown to 
result in cell death (Koul et aI., 2002). Additionally, the positive charge on COD crystals 
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is higher than that on COM crystals (Wesson et aI., 1995). The higher positive charge on 
COD crystals would prevent their adhesion to the cell surface and therefore inhibit their 
retention in the renal tubes (Wesson et a1., 1995; Cerini et aI., 1999). Thus, the production 
of COD in urine of black subjects affords them protection from stone disease because the 
COD crystals are less likely to bind to the renal epithelial cells and be retained in the 
kidney. 
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CHAPTER 4: CONCLUSION 
A study of the effect of albumin on the crystallisation of CaOx in urine of South Africa's 
population groups has not been previously undertaken. While results for white subjects 
can be compared with studies from elsewhere in the world, the black population group is 
unique and the apparent immunity of this group provided the motivation for this study. 
Following the successful isolation, purification and verification of urinary albumin from 
the two race groups, crystallisation experiments were undertaken to ascertain the effect of 
albumin on CaOx crystallisation kinetics, Coulter Counter measurements of particle 
volume-size distributions, C4C]-oxalate deposition rates, zeta-potential measurements and 
crystal sedimentation rates. Previous studies on albumin have not adopted as rigorous a 
procedure as adopted in this study - multiple techniques were employed whereas previous 
studies used only one or two. 
Data acquired by spectrophotometry, Coulter Counter and [14C]-oxalate deposition were 
considered in concert and demonstrated that albumin from both race groups inhibits the 
rate of formation of CaOx crystals. These results are in harmony with recent findings 
(Edyvane et aL, 1987; Grover et al., 1998; Chen et aL, 2001). In BUF, WA was a stronger 
inhibitor of [14C]-oxalate deposition than BA. However, the results for spectrophotometry 
and Coulter Counter indicated that BA was a superior inhibitor compared to W A. The 
discrepancy in these results was attributed to independent protein co-precipitation. In 
WUF, BA was found to be a more potent inhibitor of CaOx crystal formation. 
Results on [14C]-oxalate deposition rates in the current study demonstrated that albumin, 
irrespective of its source, inhibited CaOx crystallisation. Interestingly, previous studies 
have referred to albumin's effect on CaOx crystal growth as modest or absent (Edyvane et 
al., 1987; Worcester et al., 1988; Grover et aL, 1998; Chen et al., 2001). The reason why 
the results of the present study do not agree with that reported in literature is that different 
assay systems were used. 
Several investigators (Edyvane et al., 1987; Ryall et al., 1991; Hess et al., 1995; Grover et 
al., 1998; Cerini et al., 1999) have reported that crystals that form in the presence of 
albumin are smaller and more numerous than those in control solutions. It is worth noting 
that in all the above mentioned studies, commercial human serum albumin was used in real 
urine or in inorganic solution. The advantage of the present study over those mentioned 
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above is that urinGlY albumin was used in real urine. While there may not be any 
compositional, structural and conformational differences between human serum albumin 
(HSA) and urinary albumin, the different solutions might explain why the formation of 
smaller crystals in greater numbers, as described above, was not observed in the present 
study. 
Urine composition was also found to be important. Albumin from both race groups when 
added to BUF formed fewer crystals and their total volume was less than those crystals 
which formed in \\tuF, suggesting a synergistic relationship between protein inhibitory 
performance and urine environment. 
Another interesting observation was the formation of predominantly COD crystals in urine 
from healthy black subjects. Urine from healthy white subjects contained a mixture of 
COM and COD crystals. This was interpreted as a favourable response, as production of 
COD might afford the black group protection because COD crystals are less likely to bind 
to the renal epithelial cells and be retained in the kidney. 
An important aim of this thesis was to access whether the inhibition of aggregation by 
albumin from black subjects was superior to albumin from white subjects. Indeed results 
from the sedimentation and zeta-potential experiments have shown this to be so. In the 
presence of BA, COM crystals carry a more negative charge than in the presence of W A. 
Therefore, BA will exert stronger repulsive forces and is likely to be a superior inhibitor of 
crystal aggregation than W A. These results were confirmed by sedimentation experiments 
and agree with results published in the literature for albumin (Hess et aI., 1989). These 
results are significant because crystal aggregation is considered to be the most important 
mechanism necessary for stone formation. The present study demonstrated that BA is 
superior to W A with respect to inhibition of this mechanism. 
Therefore, the results of this thesis provide compelling evidence to suggest that it is 
reasonable to speculate that albumin may playa contributory role to the overall immunity 
of the black population group in South Africa to urolithiasis. 
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